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IAbstract
SIRT2 belongs to the protein family of sirtuins, which are homologs of the yeast silencing 
information regulator 2 (Sir2), an NAD+-dependent histone deacetylase. Seven different 
sirtuins, SIRT1-7, have been identified in mammals, which share a common catalytic core 
domain but possess distinct N- and C-terminal extensions. In the case of SIRT2 this core 
domain elicits an NAD+-dependent deacetylase activity. SIRT2 is the only sirtuin, which is 
predominantly localized in the cytoplasm. It is highly abundant in the brain, especially in 
myelin-forming oligodendrocytes. Cellular processes, in which SIRT2 is implicated, include 
differentiation, neurite outgrowth, autophagy, and spindle checkpoint activation. In addition, 
SIRT2 is associated with neurodegenerative diseases, such as Huntington's and Alzheimer's 
disease. These findings strongly suggest that SIRT2 is tightly controlled and potentially 
responsive to different signal transduction pathways. However, very little is known about how 
SIRT2 is regulated both in normal and deregulated cell physiology. Because deregulation of 
cellular processes account for many diseases, it is important to understand the mechanisms 
that determine SIRT2 function.
Here I demonstrate that a p35/CDK5-mediated signaling pathway mediates the 
phosphorylation of SIRT2 at serine 368/331 (S368/331) and S372/335 (numbering according 
to SIRT2 isoform 1 or isoform 2, respectively) in cells. Thereby p35/CDK5 phosphorylates 
S368/331 directly, whereas the phosphorylation of S372/335 is effected indirectly. A 
candidate kinase acting downstream of CDK5 is CDK16, which also induces phosphorylation 
of SIRT2 at S335 in cells. Furthermore my results support the hypothesis that the C-terminal 
region of SIRT2 administrates an inhibitory effect on the catalytic activity of SIRT2, which 
might be enhanced by phosphorylation. In addition I discovered a potential feedback-loop 
between SIRT2 and CDK5, which includes a cytoplasmic acetyltransferase, GCN5.
My results provide further knowledge about a regulatory signaling pathway that targets SIRT2 
and CDK5, two proteins involved in postmitotic cell physiology and whose deregulation 
support and are associated with neurodegeneration.
II
Zusammenfassung
SIRT2 ist eine NAD+-abhängige Deacetylase, die zur Proteinfamilie der Sirtuine gehört. Diese 
wird aus Homologen des Hefe-Proteins Sir2 gebildet. Bislang wurden sieben humane Sirtuine 
identifiziert, SIRT1-7, welche sich durch eine konservierte katalytische Domäne auszeichnen. 
Abgesehen von dieser Sirtuin-typischen Domäne unterscheiden sich die einzelnen Sirtuine in 
ihren N- und C-terminalen Regionen, für die regulatorische Eigenschaften nachgewiesen 
werden konnten. SIRT2 ist im Gegensatz zu den anderen Sirtuinen hauptsächlich im 
Zytoplasma lokalisiert. Außerdem wurden hohe SIRT2-Expressionslevel im Gehirn, 
insbesondere in den Myelin-bildenden Oligodendrozyten gemessen. SIRT2 ist in verschiedene 
zelluläre Prozesse involviert, wie zum Beispiel Zelldifferenzierung, Neuritenwachstum, 
Makroautophagie und Spindel-Kontrollpunkt-Aktivierung im Zellzyklus. Außerdem ist SIRT2 
mit neurodegenerativen Erkrankungen, wie zum Beispiel Huntington und Alzheimer, 
assoziiert. Diese Erkenntnisse deuten darauf hin, dass SIRT2 Regulationsmechanismen 
unterliegt, welche durch verschiedene Signalwege gesteuert werden können. Bisher ist nur 
wenig über solche Regulationsmechanismen für SIRT2 bekannt. Um zu verstehen, wie es zu 
bestimmten Krankheitsbildern kommt, ist es wichtig diese Regulationsmechanismen zu 
kennen.
In dieser Arbeit zeige ich, dass ein p35/CDK5-abhängiger Signalweg die Phosphorylierung 
von SIRT2 in der C-terminalen Region an Serin 368/331 (S368/331) und S372/335 
(Nummerierung gibt Position der Aminosäure in Isoform 1 oder 2 an) in Zellen vermittelt. 
P35/CDK5 phosphoryliert SIRT2 dabei an S368/331 direkt, während die Phosphorylierung 
von S372/335 jedoch indirekt erfolgt. Eine mögliche Kinase, welche durch CDK5 aktiviert 
wird, ist CDK16. Mit Hilfe von Mutationsanalysen konnte ich eine inhibierende Funktion der 
C-terminalen Region nachweisen, welche vermutlich durch Phosphorylierung verstärkt wird. 
Außerdem zeige ich einen Feedback-Signalweg zwischen SIRT2 und CDK5, welcher 
möglicherweise eine neue zytoplasmatische Funktion der Acetyltransferase GCN5 beschreibt. 
Meine Ergebnisse geben Aufschluss über einen Signalweg, der sowohl SIRT2 als auch CDK5 
reguliert: Zwei Proteine, die die postmitotische Zellphysiologie kontrollieren und deren 
Fehlregulation mit der Ausbildung von neurodegenerativen Erkrankungen assoziiert ist.
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1. Introduction 1
1. Introduction
Sirtuins are homologs of the yeast silencing information regulator 2 (Sir2) protein, an NAD+-
dependent (histone) deacetylase. In mammals 7 different sirtuins, SIRT1-7, have been 
identified, which share a common catalytic core domain but possess distinct amino- (N-) and 
carboxy- (C-) terminal extensions. This core domain elicits NAD+-dependent deacetylase and 
in some cases also ADP-ribosyltransferase activity. Sirtuins have been implicated in key 
cellular processes, including cell survival, autophagy, apoptosis, gene transcription, DNA 
repair, stress response and genome stability. In addition some sirtuins are associated with 
disease, including cancer and neurodegeneration. These findings suggest strongly that sirtuins 
are tightly controlled and potentially responsive to different signal transduction pathways. 
However, very little is known about how these proteins are regulated both in normal and 
deregulated cell physiology and as deregulation of cellular processes are the basis for many 
diseases, it is important to understand the mechanisms that determine sirtuin function.
1.1 Posttranslational modifications (PTMs)
The term “posttranslational modification” (PTM) is generally used to summarize covalent 
modifications, which are inflicted upon a protein after its translation. These can involve 
structural changes of a protein or the addition of functional groups or proteins to individual 
amino acids of a protein. Posttranslational structural changes can be achieved, e.g. by 
disulfide bridges between cysteines or by proteolytic cleavage of peptide bonds. Prominent 
functional groups, which can be added posttranslationally are acetyl- (acetylation) or 
phosphate-groups (phosphorylation). SUMOylation and ubiquitination are processes, which 
involve the addition of small proteins. More than 200 different PTMs have been described to 
date. While these are usually catalyzed by enzymes, non-enzymatic modifications occur as 
well, e.g. glycation (Wold, 1981). Within the enzyme-mediated PTM group one can 
distinguish between those that are catalyzed in an uni-directional manner and those that are 
reversible and thus can function as on-off switches for biological activities (Yan et al., 1989).
PTMs expand the functional properties of proteins as they can influence their activity, 
subcellular distribution, interactions and/or turnover (Wold, 1981).
Many proteins are posttranslationally modified in multiple ways and in some of these cases 
single PTMs can influence each other. This so-called PTM crosstalk can be of positive or 
negative nature. While in positive crosstalk one PTM mediates the removal or addition of a 
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second PTM or structural change, negative crosstalk is defined by competition between 
PTMs, e.g. SUMOylation and acetylation target the same lysine residue and thus excludes the 
other (Hunter, 2007). In another example of negative crosstalk one modification prevents 
binding of an enzyme because it masks the consensus site. Furthermore direct crosstalk 
between PTMs occurs if a modification affects the activity of a PTM-catalyzing enzyme or 
the accessibility of this enzyme to its substrate (Hunter, 2007). This complex program of 
protein regulation is essential for normal development. Thus deregulation of PTM 
mechanisms are often implicated in diseases including cancer and neurodegeneration (Rodier 
et al., 2007).
1.1.1 Phosphorylation
Reversible phosphorylation of proteins, catalyzed by protein kinases and protein 
phosphatases, can regulate protein functions in multiple ways, e.g. modifying the biological 
activity, stability, subcellular distribution or intra- and intermolecular interactions. About 
30 % of cellular proteins are shown to be phosphorylated, which reflects the importance of 
this PTM in regulation of cellular function (Cohen, 2000). Protein phosphorylation involves 
the transfer of a phosphate moiety from a donor molecule, in general ATP, to an amino acid 
residue of the target protein. There are nine amino acids in proteins, which can be 
phosphorylated (tyrosine, serine, threonine, cysteine, arginine, lysine, aspartate, glutamate and 
histidine) with serine, threonine and tyrosine being predominantly phosphorylated in 
eukaryotic cells (Moorhead et al., 2009).
Cyclin-dependent kinases (CDKs) are a protein family of kinases, which are involved in 
multiple cellular processes, such as cell cycle regulation and gene transcription. As the name 
indicates the activity of these kinases is dependent on their association with specific cyclin 
subunits. The human genome encodes 21 CDK genes (CDK1-CDK20, including CDK11A 
and CDK11B) and five additional genes for CDK-like kinases (CDKL1-5) (Malumbres et al., 
2009).
Enzymes that remove phosphate groups from eukaryotic proteins can be grouped into four 
main classes. These are termed PPPs (phospho-protein phosphatases), PPMs (metallo-
dependent protein phosphatases), PTPs (protein tyrosine phosphatases) and aspartate-based 
phosphatases. In contrast to its name the PTP class is defined by the catalytic signature CX5R 
rather than a common substrate preference. The majority of PTPs dephosphorylates 
phosphotyrosine. In some cases, however, phosphoserine and -threonine are targeted. The 
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PTP class can be further subdivided into subclass I and class II PTPs with class I containing 
the classic and dual-specific enzymes (DUSPs) (Moorhead et al., 2009).
There are several cases, in which a crosstalk between phosphorylation and other PTMs is 
reported, e.g. with ubiquitination. This crosstalk takes place at several levels as 
phosphorylation can modify the activity of E3 ligases, influence the recognition of a protein 
by an E3 ligase or influence the accessibility of a protein for an E3 ligase in a temporal-spatial 
manner by regulating their subcellular distribution (Hunter, 2007).
1.1.2 Acetylation
In vivo lysine acetylation as a PTM was initially described 47 years ago (Allfrey and Mirsky, 
1964). To date at least 1750 acetylated proteins have been identified in mammals. 
Comparative analysis revealed that acetylation sites are significantly higher conserved than 
phosphorylation sites (Choudhary et al., 2009; Choudhary et al., 2011). Because the first 
acetylated proteins described were histones, enzymes catalyzing the addition or removal of 
acetyl groups are often referred to as histone acetyltransferases (HATs) or histone 
deacetylases (HDACs). As many of these enzymes are subsequently shown to target non-
histone targets as well, Allis and colleagues introduced in 2007 a new nomenclature, in which 
HATs became lysine acetyltransferases (KATs) (Allis et al., 2007). Accordingly HDACs are 
sometimes referred to as KDACs (lysine deacetylases).
Based on structural and functional similarities, mammalian KDACs can be divided into four 
major classes. Class I KDACs are similar to yeast Rpd3 and contain HDAC1, -2, -3 and -8 
whereas class II KDACs are homologs of yeast Hda1 and include HDAC4, -5, -6, -7, -9 and 
-10. Sirtuins, which are related to yeast Sir2 are also termed class III KDACs and HDAC11 
forms the class IV on its own (Voelter-Mahlknecht et al., 2006).
Beside acetylation, lysine side chains are also targeted by other PTMs, e.g. ubiquitination, 
SUMOylation or methylation. As these PTMs cannot occur simultaneously on the same 
lysine, acetylation has the potential for negative cross-regulation (Yang and Seto, 2008).
Furthermore acetylation can crosstalk with phosphorylation. For example it was recently 
reported that acetylation regulates the subcellular localization of the kinases AKT and PDK1 
and thus their substrate-accessibility (Sundaresan et al., 2011).
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1.1.3 ADP-ribosylation
ADP-ribosylation, which was first observed by P. Chambon and colleagues in 1963 
(Chambon et al., 1963) can be grouped into four major reaction types: mono-ADP-
ribosylation, poly-ADP-ribosylation, ADP-ribose cyclization and formation of O-acetyl-ADP-
ribose. However, only the first two reactions are involved in posttranslational modification of 
proteins, while the products of the latter two reaction types are thought to function as second 
messengers. ADP-ribosylation is carried out by ADP-ribosyltransferases (ARTs) and involves 
the transfer of an ADP-ribose moiety from NAD+ to a specific amino acid residue of a 
substrate, typically a protein. Simultaneously nicotinamide is released. The type of amino acid 
residue that is mono-ADP-ribosylated depends on the specificity of the distinct mono-ART. 
Bacterial mono-ARTs are reported to target amino acids including arginine, asparagine, 
glutamate, aspartate, cysteine, and modified histidine. Non-enzymatic mono-ADP-
ribosylation can occur at lysine or cysteine residues. Poly-ADP-ribosylation (PAR) describes 
the formation of an homopolymer of ADP-ribose molecules, which are linked by glycosidic 
bonds as the result of an iterative transfer of multiple ADP-ribose units to substrates by ARTs. 
These polymers can have varying lengths of up to 400 ADP-ribose units. ADP-ribosylation is 
a reversible process and ADP-ribose is removed from substrates by glycohydrolases that are 
still ill defined (Hottiger et al., 2010).
There is an interesting link between PARylating enzymes and sirtuins. The majority of sirtuins 
catalyzes an NAD+-dependent deacetylase reaction (Smith et al., 2000). Therefore one NAD+ 
is cleaved between nicotinamide and ADP-ribose for each acetyl group that is removed from a 
substrate (Landry et al., 2000). The ADP-ribose moiety is necessary for the deacetylase 
reaction as it serves as an acceptor for the removed acetyl group and forms a novel O-acetyl-
ADP-ribose (O-AADPr) product (Tanner et al., 2000). In addition selected sirtuins are also 
reported to catalyze an NAD+-dependent ADP-ribosyltransfer reaction (Liszt et al., 2005; 
Ahuja et al., 2007). This tight connection between sirtuin reactions and ADP-ribosylating 
enzymes provides potential for crosstalk. Thus Zhang et al. suggested in 2003 that the 
competition for NAD+ links both reaction types (Zhang, 2003).
1.1.4 Methylation
The transfer of a methyl group to an amino acid residue is termed methylation and the most 
common substrates are lysines or arginines of histones and non-histone proteins. Methylation 
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catalyzing enzymes (methyltransferases) use S-adenosyl-L-methionine (SAM) as a methyl 
donor generating the methylated substrate and S-adenosyl-L-homocysteine as a by-product. 
Lysine methyltransferases (KMTs) catalyze the transfer of up to three methyl groups to the ε-
nitrogen of lysine residues thereby generating mono-, di- or trimethylated residues. They are 
specified according to a conserved SET domain that facilitates the interaction with the 
targeted lysine and the binding of SAM, e.g. SET7/9. The SET domain is named after the 
three Drosophila proteins, in which this conserved region was originally identified: 
SU(VAR)39, Enhancer of zeste,  and Trithorax (Pradhan et al., 2009). KMTs target 
predominantly lysine residues in N-terminal histone tails thereby contributing to the so-called 
“histone code”. These modifications together with other posttranslational histone 
modifications are involved in the control of chromatin structure and DNA accessibility for 
replication, repair, and transcription (Strahl and Allis, 2000). Few non-histone proteins such as 
the tumor suppressor p53 are also reported to be subject to lysine methylation. On the other 
hand, many protein arginine methyltransferases (PRMTs) can catalyze methylation of non-
histone proteins. In particular, shuttling proteins are a target of arginine methylation. Arginine 
methylation involves the transfer of one or two methyl groups to the ω-nitrogen of the 
guanidinium side chain of arginine. The resulting dimethylarginines are either symmetric or 
asymmetric (Di Lorenzo and Bedford, 2011).
At least lysine methylation is a reversible modification. Thus in 2004 Shi et al. discovered a 
lysine specific demethylase (KDM) that is able to demethylate mono- and dimethylated 
lysines. It uses FAD as a co-factor and generates formaldehyde and hydrogen peroxide as by-
products (Pradhan et al., 2009).
1.1.5 Ubiquitination
Ubiquitination is an ATP-requiring PTM, in which a small protein (ubiquitin) is covalently 
bound to a primary amino group on the acceptor protein. In general, ubiquitin is linked either 
to the ε-amino group of a lysine residue or to the N-terminus of a polypeptide (Ciechanover 
and Ben-Saadon, 2004). However, it has been reported that ubiquitin can additionally be 
attached to cysteine, serine and threonine residues in proteins (Hochstrasser, 2009).
Ubiquitin consists of 76 amino acids and has a predicted molecular size of 8.4 kDa. It is 
sequentially activated and attached to acceptor proteins by a series of enzymes, which are 
termed according to their functions ubiquitin-activating enzyme (E1), ubiquitin-conjugating 
enzyme (E2) and ubiquitin-ligating enzyme (E3). Out of these three types of enzymes E3-
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ligases determine the substrate specificity of the reaction. There are seven lysine residues in 
ubiquitin itself (K6, K11, K27, K29, K33, K48 and K63) allowing further conjugation of 
another ubiquitin to form a polyubiquitin chain. The linkage between ubiquitin-subunits 
within a chain can be homo- or heterotypic with homo-K48- or homo-K63-linked chains 
being the most common types (Pickart, 2001).
The attachment of ubiquitin can have different effects on the acceptor protein. Whereas 
monoubiquitination is reported to alter protein activity or subcellular distribution, 
polyubiquitin chains can serve as signals for degradation, immune signaling or DNA repair. 
These modifications are recognized by different types of ubiquitin-binding domains (UBDs) 
(Dikic et al., 2009).
Ubiquitination is reversible as ubiquitin can be removed from a protein by enzymes known as 
deubiquitinating enzymes (DUBs) (Amerik and Hochstrasser, 2004). To date two ubiquitin E1 
enzymes, and about 50 E2s, 600 E3s, 90 DUBs and 20 types of UBDs have been identified in 
the human proteome (Bhoj and Chen, 2009).
1.1.6 SUMOylation
SUMOylation shares substantial similarities with ubiquitination as it includes the reversible 
attachment of small ubiquitin-related modifiers (SUMOs) to internal lysine residues of 
substrate proteins in a posttranslational manner. SUMOs resemble ubiquitin in their three-
dimensional structure but they share only ~18 % amino acid sequence homology. Four human 
SUMO proteins have been identified so far (SUMO1-4). Similar to ubiquitin they are 
synthesized as immature preforms, which need to be cleaved at the C-terminus before 
conjugation to a substrate. The actual mechanism for SUMOylation proceeds in a similar 
three-step way as ubiquitination with the alteration that E1-E3 enzymes are SUMO-specific 
(Geiss-Friedlander and Melchior, 2007). SUMOylation occurs at a short consensus sequence 
ΨKXE, in which Ψ is a large hydrophobic (isoleucine, leucine, or valine) and X any amino 
acid (Song et al., 2004). In general, SUMOylation results in attachment of a single moiety. 
However, an unstructured N-terminal extension of SUMO proteins can mediate the formation 
of polySUMO chains as is regularly observed for ubiquitin. The removal of SUMO 
modifications is carried out by specific proteases, which are also responsible for the 
generation of mature SUMO forms by cleaving the preforms. Six proteases have been 
identified in humans that are responsible for SUMO processing, and which are termed sentrin-
specific proteases (SeNP1-3, SeNP5-7). They are homologues of yeast Ulp1 and Ulp2 (Geiss-
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Friedlander and Melchior, 2007).
SUMOylation usually positively regulates protein-protein interactions thereby promoting the 
assembly of multi-protein complexes. Thus it is involved in transcriptional regulation, nuclear 
transport, maintenance of genome integrity, and signal transduction. The modification can be 
recognized by so-called SUMO-interaction motifs (SIMs), which consist of a hydrophobic 
core that is enclosed by up to five acidic amino acids (Johnson, 2004).
Crosstalk of SUMOylation with other PTMs has been observed for phosphorylation, 
ubiquitination, and acetylation. For example a phosphorylated serine and proline residue 
following the SUMO-motif can enhance SUMOylation (Hietakangas et al., 2006). 
Furthermore phosphorylation-dependent SIMs have been reported, which recognize SUMO 
only after phosphorylation. Negative crosstalk occurs if SUMO and ubiquitin and also 
acetylation target the same lysine (Desterro et al., 1998). Additionally, crosstalk between 
ubiquitination and SUMOylation takes place when enzymes of one system are modified by 
the other system (Prudden et al., 2007). This interplay is also observed for acetylation as for 
example SIRT1 is SUMOylated and thereby its activity enhanced (Yang et al., 2007).
1.1.7 Posttranslational mitochondrial translocation and proteolytic 
cleavage
Usually, inner-mitochondrial proteins are synthesized as precursor proteins with N-terminal 
extensions, which are cleaved off during passage into the mitochondria (Chacinska et al., 
2009). These so-called presequences are recognized in the cytoplasm by chaperones, which 
maintain an “import-competent” conformation of the precursor and prevent its aggregation 
and degradation. Furthermore the presequences contain a positively charged mitochondrial 
matrix-targeting signal of up to 60 amino acid residues, which is often followed by an intra-
mitochondrial sorting signal. These signals determine whether the mature protein is localized 
in the mitochondrial matrix, inner-membrane or inter-membrane space (Chacinska et al., 
2009). Mitochondrial import of precursor proteins is driven by the TIM/TOM-complex 
system. Therefore the precursor is translocated across the mitochondrial outer membrane by 
electrostatic interactions between the positively charged presequence and proteins of the 
“translocase of the outer membrane” (TOM) complex. Then the precursor is pulled across the 
inner membrane via the “translocase of the inner membrane” (TIM) complex in an ATP-
dependent manner. In the mitochondrial matrix the matrix targeting signal of the presequence 
is cleaved off by the mitochondrial processing peptidase (MPP) thereby unmasking potential 
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intra-mitochondrial sorting signals. In most cases MPP-cleavage generates a biologically 
active protein. However, there are mitochondrial proteins that require an additional cleavage 
by the mitochondrial intermediate peptidase (MIP) to become fully active. Inter-membrane 
space proteins often undergo an additional cleavage by the inner membrane peptidase (IMP) 
during their passage back across the inner membrane (Gakh et al., 2002).
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1.2 Sirtuins and their regulation by PTMs
The sirtuin protein family was founded by the yeast silent information regulator 2 (Sir2) 
(Brachmann et al., 1995). Sir2 is a nicotinamide adenine dinucleotide (NAD+)-dependent 
histone deacetylase (Imai et al., 2000) and initial findings from genetic studies suggested that 
Sir2 controls chromatin and gene expression. In particular Sir2 was identified to participate in 
silencing of homothallic mating (HM) loci and telomeric chromosomal regions and to 
interfere with rDNA recombination (Braunstein et al., 1993; Gottlieb and Esposito, 1989). 
These functions have obtained wide interest because they have been linked to lifespan 
regulation. Indeed overexpression of Sir2 was shown to increase lifespan in yeast (Kaeberlein 
et al., 1999). Although similar effects were reported for Drosophila melanogaster and 
Caenorhabditis elegans, more recent findings suggest that Sir2 does not affect longevity in 
these organisms (Burnett et al., 2011).
Sir2-like proteins are conserved from prokaryotes to mammals and they all share a common 
core domain comprising approximately 200-275 amino acid residues. A phylogenetic analysis 
of the catalytic domain allows subdividing the sirtuin into five classes, i.e. I-IV and U, with 
the latter only found in gram-positive bacteria (Frye, 2000). Besides the founding member 
Sir2, the yeast Saccharomyces cerevisiae expresses four additional sirtuin genes, whose gene 
products are termed “homologs of sir two” (Hst1-4). Seven human sirtuins have been 
identified so far, which can be grouped into four of the phylogenetic classes: SIRT1, SIRT2 
and SIRT3 (class I), SIRT4 (class II), SIRT5 (class III) and SIRT6 and SIRT7 (class IV) (Frye, 
2000). Of these, SIRT1 share the highest sequence similarities with yeast Sir2 and Hst1, and 
SIRT2 and SIRT3 with Hst2. SIRT4 to SIRT7 are more closely related to prokaryotic sirtuins 
or sirtuins of Drosophila melanogaster and Caenorhabditis elegans (Figure 1).
The mammalian sirtuins are localized in different subcellular compartments. While SIRT1, 
SIRT6 and SIRT7 are predominantly localized in the nucleus, albeit with different subnuclear 
distributions, SIRT3, SIRT4 and SIRT5 are mitochondrial. SIRT2 is the only human sirtuin, 
which is primarily localized in the cytoplasm (Michishita et al., 2005).
The majority of sirtuins catalyzes an NAD+-dependent deacetylase reaction (Smith et al., 
2000). Therefore one NAD+ is hydrolyzed for each acetyl group removed from a substrate 
with the nicotinamide moiety being released (Landry et al., 2000). The acetyl group is 
transferred to ADP-ribose to form a novel O-acetyl-ADP-ribose product (Tanner et al., 2000), 
which has been suggested to function as a second messenger (Tong and Denu, 2010). 
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Additionally, distinct sirtuins (SIRT4 and SIRT6) were reported to catalyze the transfer of 
ADP-ribose from NAD+ to substrate proteins (Ahuja et al., 2007; Liszt et al., 2005), thus 
providing evidence that some sirtuins may be able to perform two different biochemical 
reactions.
The findings summarized above, including the observations on longevity in yeast, the role of 
NAD+ as cofactor, and the localization of the different sirtuins to distinct subcellular 
compartments, notably the mitochondria, suggested early on that sirtuins might have 
Figure 1: Phylogenetic classification of Sirtuins derived from phylogenetic analysis of the conserved domains of 
60 sirtuin sequences. Classes I, II, III, IV, and U and subdivisions of classes I and IV are indicated. Organism 
abbreviations: A. act, Actinobacillus actinomycetemcomitans; A. aeo, Aquifex aeolicus; A. ful, Archaeoglobus 
fulgidus; A. per, Aeropyrum pernix; A. tha, Arabidopsis thaliana; B. per, Bordetella pertussis; B. sub, Bacillus  
subtilis; C. ace, Clostridium acetabutylicum; C. alb, Candida albicans; C. dif, Clostridium difficile; C. ele,  
Caenorhabditis elegans; C. jej, Campylobacter jejuni; D. mel, Drosophila melanogaster; D. rad, Deinococcus  
radiodurans; E. col, Escherichia coli; E. fae, Enterococcus faecalis; H. sap, Homo sapiens; H. pyl, Helicobacter  
pylori; L. maj, Leishmania major; M. avi, Mycobacterium avium; M. tub, Mycobacterium tuberculosis; O. sat,  
Oryza sativa; P. aby, Pyrococcus abyssi; P. fal, Plasmodium falciparum; P. hor, Pyrococcus horikoshii; S. aur,  
Staphylococcus aureus; S. coe, Streptomyces coelicolor; S. pom, Schizosaccharomyces pombe, S. typ,  
Salmonella typhimurium; S. cer, Saccharomyces cerevisiae; T. bru, Trypanosoma brucei; T. mar, Thermotoga  
maritima; Y. pes, Yersinia pestis (North and Verdin, 2004).
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fundamental roles in metabolism. Indeed Sir2 is mediating at least in part the effects elicited 
by caloric restriction (Lu and Lin, 2010). Of note is also that sirtuins in higher organisms have 
been suggested to contribute to longevity (Guarente, 2011). Moreover the findings that 
sirtuins carry out NAD+-dependent reactions suggest an involvement of these enzymes in 
mammalian metabolic control and offer the possibility for modulation of their activity by 
small molecules. The involvement of sirtuins in many physiological processes (see also 
below) suggests that these enzymes themselves are most likely controlled by different 
signaling pathways in response to both extracellular and intracellular cues. The use of NAD+ 
must be controlled because of its central function in metabolic pathways, suggesting that 
enzymes that consume NAD+ will most likely be part of feedback control mechanisms of such 
pathways. In addition the enzymatic processes of deacetylation and of ADP-ribosylation need 
to be regulated to adjust for optimal, functionally relevant levels of substrate acetylation and 
ADP-ribosylation. Despite the many reasons for posttranslational control of sirtuin function, 
we know relatively little about such mechanisms. The available evidence suggests that the N- 
and C-terminal extensions relative to the catalytic core domains of the seven mammalian 
sirtuins are targets of PTMs, while hardly any information is available on how the catalytic 
domain itself is controlled (Figure 2).
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Figure 2: Schematic overview of human sirtuins and their PTMs. The seven mammalian sirtuins are 
schematically indicated with the blue boxes depicting the sirtuin-typic catalytic core domain. The catalytic 
domains are flanked by distinct N- and C-terminal extensions (grey boxes). The numbers below indicate amino 
acid numbers for orientation. Two isoforms (IF) are shown for SIRT2 and SIRT5, respectively. The ESA 
(“essential for SIRT1 activity”) sequence of SIRT1 (see below) is indicated. PTMs, nuclear localization 
sequences, nuclear export sequences, and proteolytic cleavage sites are indicated.
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1.2.1 SIRT1
Among the seven human sirtuins SIRT1 shares the highest sequence homology with yeast 
Sir2 (Voelter-Mahlknecht and Mahlknecht, 2006). In addition SIRT1, similar to its ancestor 
Sir2, is localized in the nucleus and involved in chromatin remodeling as it deacetylates 
several lysine residues of histone tails, including acetylated lysines 9 of histones H3 
(H3K9ac), H3K14ac, H4K16ac, and H1K26ac (Vaquero et al., 2004). Moreover SIRT1 
targets also non-histone proteins and its activity can be regulated by its ability to shuttle 
between nuclear and cytoplasmic compartments (Tanno et al., 2007; Hisahara et al., 2008). 
The increasing number of known SIRT1 substrates includes the transcription factor and tumor 
suppressor p53  as well as several other transcriptional regulators and cofactors, among them 
NF-κB, members of the forkhead family (FOXOs), PPAR (peroxisome proliferator-activated 
receptors) and p300 (Rahman and Islam, 2011). Molecular studies revealed that SIRT1 is 
involved in the regulation of diverse cellular processes ranging from lipid and glucose 
metabolism, cancer, aging to stress response. Of particular relevance for many of these 
processes is the AMP-activated protein kinase (AMPK)-SIRT1 signaling axis. AMPK is 
activated in response to increasing amounts of AMP and thus functions as an energy sensor 
that responds to cellular metabolic stress, including calorie restriction. Thereupon it increases 
the intracellular NAD+/NADH ratio in a nicotinamide (NAM) phosphoribosyltransferase 
(NAMPT)-dependent way, promoting the activity of SIRT1 (Fulco et al., 2008). Maybe not 
surprising then is the finding that Sirt1 knockout mice display a severe phenotype. These mice 
are viable but sterile and have a high prenatal or early postnatal death rate. Surviving animals 
are smaller than their wildtype littermates and exhibit developmental defects, e.g. delayed 
eyelid opening. Furthermore they are reported to suffer from several dysfunctions of the heart, 
lung and pancreas (Cheng et al., 2003; McBurney et al., 2003).
With the identification of the tumor suppressor p53 as a SIRT1 substrate, a role of this 
enzyme in tumor formation was postulated (Vaziri et al., 2001; Luo et al., 2001). Upon 
deacetylation by SIRT1, the activity of p53 is reduced and thus SIRT1 appears to function as 
an oncoprotein (Chen et al., 2005; Kim et al., 2007; Yuan et al., 2011). However, there are 
also reports that describe SIRT1 as a tumor suppressor (Yi and Luo, 2010). These alternative 
activities are possibly the result of cell-type specific effects and/or a consequence of distinct 
regulation of SIRT1 that might differentially affect the activities of substrates.
SIRT1 is ubiquitously expressed with highest mRNA levels measured in the brain, skeletal 
muscle, kidney and thymus (Michishita et al., 2005).
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Despite being the best studied human sirtuin relatively little is known about mechanisms that 
regulate SIRT1 itself. The 747 amino acids long protein is by far the largest human sirtuin, 
due to its extensive N- and C-terminal sequences (Figure 2). SIRT1 has a predicted molecular 
size of 81.7 kDa and the conserved catalytic domain is found between amino acid residues 
244 and 498 (Voelter-Mahlknecht and Mahlknecht, 2006). The N-terminal extension of SIRT1 
contains two functional nuclear localization signals (NLS) between amino acid residues 31-38 
and 223-230. These are counteracted by two nuclear export signals (NES) between amino 
acid residues 138-145 and 425-431. Both types of signal sequences are responsible for the 
nucleo-cytoplasmic shuttling of SIRT1 (Tanno et al., 2007), which determines at least in part 
the enzyme's ability to interact with distinct substrates (Hisahara et al., 2008). Furthermore the 
nuclear-cytoplasmic distribution of SIRT1 is regulated by signals, for example during 
differentiation (Tanno et al., 2007). While SIRT1 is nuclear in proliferating C2C12 myoblasts, 
it is cytoplasmic in differentiated cells. Moreover inhibition of PI3K prevents the nuclear 
localization of SIRT1 in proliferating cells, suggesting that PI3K-dependent signaling controls 
the shuttling. Whether the PI3K signaling cascade targets directly SIRT1 or some accessory 
factor or factors is not known. One kinase that might be involved in this process is JNK, 
although this kinase is not typically activated downstream of PI3K. JNK interacts with SIRT1 
upon oxidative stress, phosphorylates SIRT1 at S27, S47, and T530, thereby enhancing its 
nuclear localization (Nasrin et al., 2009). Furthermore these phosphorylations increase the 
enzymatic activity of SIRT1 in a substrate-specific manner with histone H3, but not p53, 
becoming a better substrate. In contrast to the findings with JNK, mTOR-dependent 
phosphorylation of S47 alone results in inhibition of SIRT1 deacetylase activity (Back et al., 
2011). Thus combinatorial effects of different phosphorylations appear to control SIRT1 
function. 
Using a mass spectrometry approach, 13 phosphorylation sites were identified in SIRT1 
(Sasaki et al., 2008a). Seven of these sites are located in the N-terminal region, including S27 
and S47, and six in the C-terminal region, including T530 (Figure 2). Two of the identified 
sites, T530 and S540, are potential substrates of cyclin B/cyclin-dependent kinase 1 (CDK) 
complexes. The functional analysis suggests that these two phosphorylation sites are required 
for normal cell cycle progression. For example, while wildtype SIRT1 rescues the growth 
defect of cells lacking endogenous SIRT1, a mutant, in which T530 and S540 are substituted 
by alanines, is unable to rescue the knockout cells (Sasaki et al., 2008a).
In addition to the sites mentioned above, two protein kinase CK2 phosphorylation sites have 
1. Introduction 15
been identified at S659 and S661 in the C-terminal extension (Zschoernig and Mahlknecht, 
2009). Although it is not fully clear if these sites are also used in cells because they were not 
identified in the mass spectrometry approach described above and no site-specific antibodies 
have been reported, these phosphorylation sites are potentially of considerable functional 
relevance. They lie within a domain of SIRT1 that is referred to as the ESA (for essential for 
SIRT1 activity) (Figure 3), which spans a small region from amino acids 641 to 665 in human 
SIRT1 (Kang et al., 2011). The ESA interacts with the catalytic domain, activates the catalytic 
activity, and increases the affinity for substrates. Moreover the binding site for ESA in the 
catalytic domain is also the interaction site of DBC1, an endogenous SIRT1 inhibitor (Kim et 
al., 2008). The two postulated CK2 phosphorylation sites flank one of the two identified key 
residues within ESA that are important to control catalytic activity (Figure 3). Thus it is well 
possible that these phosphorylation sites modulate the interaction of the C-terminal region 
with the catalytic domain, thereby regulating SIRT1 activity and substrate recognition and 
possibly the interaction with DBC1. Thus the control of SIRT1 function by its own C-terminal 
domain and the regulation of this interaction by CK2, although molecularly not fully explored 
yet, may represent an important regulatory mechanism (Figure 3).
Besides phosphorylation, SIRT1 is modified by additional PTMs, including sumoylation. 
SUMO, a small ubiquitin-related modifier, can be attached in vitro close to the C-terminal end 
of SIRT1 at lysine 734 (K734), which lies within a sumoylation consensus sequence (ΨKXE). 
This modification increases catalytic activity as measured by p53 deacetylation (Yang et al., 
2007). Upon stress SIRT1 associates with the nuclear desumoylase SENP1, which reduces the 
catalytic activity of SIRT1 and consequently allows efficient activation of p53. How 
modification by SUMO stimulates the catalytic activity of SIRT1 is not known. However, the 
recent findings that the C-terminal region is key to enhance SIRT1 activity suggests that 
sumoylation may participate in this regulation. A possibility is that sumoylation enhances the 
interaction of the ESA motif with the catalytic domain or modifies CK2 phosphorylation 
(Figure 3). Thus it appears that sumoylation of SIRT1 is relevant for stress control in cells. 
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Furthermore, SIRT1 is also targeted by methylation. The methyltransferase Set7/9 interacts 
with and methylates SIRT1 at K233, K235, K236, and K238 of the N-terminal extension. 
Although it is unclear whether methylation affects directly SIRT1 deacetylase activity, the 
interaction of Set7/9 with SIRT1 disrupts the binding of SIRT1 with p53. Consequently p53 
acetylation and transactivating activity is enhanced (Liu et al., 2011). Despite the lack of 
information about direct consequences of lysine methylation, it is worth remembering that 
lysines can be modified by multiple PTMs and thus methylation may compete with 
acetylation and ubiquitination (Yang and Seto, 2008).
Recently it was reported that nuclear SIRT1 is transnitrosylated by nitrosylated GAPDH 
(Kornberg et al., 2010). As a consequence acetylation of PGC1α, a SIRT1 substrate, increases 
Figure 3: Control of SIRT2 catalytic activity by the ESA motif and hypothetical regulation by phosphorylation. 
The CK2 phosphorylation sites lie within the ESA (“Essential for SIRT1 activity”) sequence motif found in the 
C-terminal extension of SIRT1. The two phosphorylation sites flank one of the two key residues of the ESA 
motif. CK2-mediated phosphorylation might either enhance the interaction of ESA with the catalytic core 
thereby increasing SIRT1 affinity for substrates or weaken the interaction. The latter scenario would allow DBC1 
to bind SIRT1 more efficiently and thus interfere with SIRT1 activity.
1. Introduction 17
in cells, suggesting that SIRT1 deacetylation activity is inhibited by nitrosylation. Mutational 
analysis implies that two cysteines, C387 and C390, within the catalytic core of SIRT1 are 
targeted by nitrosylation. These cysteines are of special interest because they participate in the 
coordination of a structurally relevant Zn2+ ion and nitrosylation might result in protein 
misfolding (Kornberg et al., 2010). It will be of interest to define whether nitrosylation is a 
general regulatory mechanism of sirtuins.
Similar to yeast Hst2, purified endogenous SIRT1 can exist as a homotrimer (Zhao et al., 
2003; Vaquero et al., 2004). Because SIRT2 was also purified as a homotrimer (Vaquero et al., 
2006), this structural organization may be characteristic for sirtuins. Structural analysis of the 
Hst2 trimer suggests that the N-terminal region is involved in trimer formation. Whether this 
is also true for SIRT1 and SIRT2 remains to be determined. Because of the many PTMs that 
have been mapped in the N-terminal extension of SIRT1, it is well possible that trimer 
formation is regulated by signaling, an aspect that needs further exploration.
1.2.2 SIRT2
SIRT2 is the only sirtuin that is predominantly localized in the cytoplasm (Afshar and 
Murnane, 1999). There, it colocalizes at least in part with the microtubule network. Consistent 
with this finding is that K40 of α-tubulin is a SIRT2 substrate (North et al., 2003). Moreover, 
SIRT2 can also translocate into the nucleus and a predominant nuclear or chromatin-
associated SIRT2 localization is detected during G2/M transition and in mitosis of the cell 
cycle in chemically synchronized cells (Vaquero et al., 2006; North and Verdin, 2007a). 
Nuclear substrates of SIRT2 include H4K16ac and H3K56ac, modifications that are 
implicated in DNA damage response and cancer (Vaquero et al., 2006; Vempati et al., 2010).
Human SIRT2 is ubiquitously expressed in at least two isoforms. The longer SIRT2 isoform 1 
consists of 389 amino acids and has a predicted molecular size of 43.2 kDa, whereas SIRT2 
isoform 2 lacks the first 37 N-terminal amino acids of isoform 1 and spans a total length of 
352 amino acids with a predicted molecular size of 39.5 kDa (Figure 2). The catalytic domain 
of SIRT2 isoform 1 and 2 is found between amino acids 84-268 and 47-231, respectively 
(Voelter-Mahlknecht et al., 2005). Highest SIRT2 mRNA levels were measured in human 
brain, heart and skeletal muscle tissues (Afshar and Murnane, 1999; Michishita et al., 2005; 
Voelter-Mahlknecht et al., 2005). Particularly high SIRT2 protein level in the brain are found 
in myelin-forming oligodendrocytes (OLs) (Li et al., 2007; Southwood et al., 2007). There, 
SIRT2 level increase after birth and peak at adulthood, thereby correlating with expression 
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profiles of the OL differentiation markers CNPase (2′,3′-cyclic nucleotide 3′-
phosphodiesterase) and MBP (myelin basic protein) (Li et al., 2007; Werner et al., 2007; Ji et 
al., 2011). In mature OLs SIRT2 abundantly resides in the myelin sheath surrounding the axon 
(Southwood et al., 2007). However, its physiological function in these postmitotic cellular 
structures remains to be elucidated. Interestingly only the shorter isoform 2 is present in the 
myelin-enriched fraction of adult mouse brain or in the cytoplasm of murine cerebellar 
granule cells (Suzuki and Koike, 2007; Werner et al., 2007), suggesting that the N-terminal 
region is involved in controlling the subcytoplasmic localization. 
Luthi-Carter et al. demonstrated recently that SIRT2 positively regulates the transcription 
factor SREBP-2 (sterol response element binding protein 2) thereby promoting cholesterol 
biosynthesis in neurons (Luthi-Carter et al., 2010). Cholesterol influences membrane 
thickness and fluidity and is essential for myelin membrane growth (Saher et al., 2005). In 
contrast, cholesterol is also reported to have a detrimental effect in neurons and presents a risk 
factor in neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s diseases (PD) 
(Stefani and Liguri, 2009; Huang et al., 2011). Consistently, Luthi-Carter et al. reported in 
2010 that SIRT2 inhibition reduces toxicity of mutant huntingtin by decreasing sterol 
biosynthesis (Luthi-Carter et al., 2010). Furthermore, SIRT2 knockdown or SIRT2 inhibition 
decreases α-synuclein toxicity, which is a hallmark of the neurodegenerative PD (Outeiro et 
al., 2007).
Besides SREBP-2, SIRT2 is also involved in the regulation of other transcription factors like 
NF-κB (Rothgiesser et al., 2010), FOXO1 (Jing et al., 2007; Zhao et al., 2010b), and FOXO3 
(Wang et al., 2007; Wang and Tong, 2009), thereby providing potential for regulation of 
multiple cellular processes, e.g. inflammation, autophagy and stress response.
The predominant cytoplasmic localization of SIRT2 is dictated by an NES in its N-terminal 
extension (amino acids 41-51 and 4-14 of the long and short protein variants, respectively) 
(Wilson et al., 2006; North and Verdin, 2007a). However, it is unclear how SIRT2 translocates 
into the nucleus, because the protein lacks any obvious NLS and it also remains to be defined 
how the cell cycle-dependent nuclear localization is regulated. One possibility is that signals 
in late G2 control the activity of the NES. Indeed in chemically synchronized cells SIRT2 is 
hyperphosphorylated during the G2/M transition and in M phase, which is paralleled by a 
mobility shift in SDS-PAGE (Dryden et al., 2003; North and Verdin, 2007b). This correlates 
with the nuclear translocation of SIRT2 and suggests a regulatory role for Cyclin B/CDK1 
and other mitose-specific kinases (Morgan, 2008). But alternative mechanisms may also be in 
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place, such as stimulation of nuclear uptake and/or tight interaction with nuclear structures in 
late G2 or mitosis.
To date two putative phosphorylation sites have been identified in SIRT2 (Figure 2). They are 
located in the C-terminal extension in close proximity to each other at S368/331 and 
S372/335 (numbering according to the two SIRT2 isoforms). The phosphorylation of each site 
results in a mobility shift of the protein in SDS-PAGE, which results in a characteristic triple 
band pattern (Nahhas et al., 2007; Pandithage et al., 2008). S368/331 is part of a cyclin-
dependent kinase (CDK) consensus motif and has been demonstrated to be a substrate of 
Cyclin B/CDK1, Cyclin E/CDK2, Cyclin A/CDK2, Cyclin D3/CDK4 and p35/CDK5 (North 
and Verdin, 2007b; Pandithage et al., 2008). Consistent with these in vitro studies is the 
finding that S368/331 is phosphorylated when cells enter S phase, suggesting that this 
phosphorylation is not the signal for nuclear accumulation of SIRT2, which begins in late G2 
(Pandithage et al., 2008). Phosphorylation of SIRT2 at S368/331 reduces its enzymatic 
activity as measured by deacetylation of core histones and α-tubulin (Pandithage et al., 2008). 
Moreover SIRT2 interferes with neurite outgrowth in primary neurons, correlating with α-
tubulin deacetylation, a process that is antagonized by phosphorylating S368/331 providing 
evidence that the C-terminal extension of SIRT2 controls activity in cells (Pandithage et al., 
2008). So far, nothing is known about a kinase responsible for phosphorylation of S372/335 
or about its influence on SIRT2 functions.
Additionally SIRT2 is acetylated by the KAT p300. This acetylation, although the site of 
modification has not been mapped, interferes with the catalytic activity of SIRT2 (Han et al., 
2008). Predictions of acetylation sites indicate that the C-terminal extension provides multiple 
target lysine residues (Li et al., 2006), further supporting the concept that the N- and C-
terminal regions are particularly relevant to control catalytic activities of sirtuins.
Finally, SIRT2 was purified as a homotrimer out of cell extracts similar to SIRT1 and Hst1 
(see above) (Vaquero et al., 2006). It is not known how trimer formation is regulated and what 
the consequences are for SIRT2 function.
1.2.3 SIRT3
Three sirtuins are located in mitochondria. Of these SIRT3 is the best studied. It is broadly 
expressed including brown but not white adipose tissue (Shi et al., 2005). Indeed, SIRT3 is 
required for PGC-1α-mediated differentiation of brown adipose tissue in an estrogen-related 
receptor α (ERRα)-dependent manner (Giralt et al., 2011; Kong et al., 2010). The 
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transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha) regulates genes involved in energy metabolism, suggesting that SIRT3 
participates in this process (Shi et al., 2005). Moreover, SIRT3 regulates the cellular response 
to oxidative stress and calorie restriction. Thus, upon cellular stress, e.g. increase in reactive 
oxygen species or nutrient deprivation, human SIRT3 transcription is stimulated (Shi et al., 
2005; Chen et al., 2011), and the protein translocates to the mitochondrial inner membrane 
(IMS) (Scher et al., 2007; Michishita et al., 2005), where it becomes activated by proteolytic 
cleavage (Schwer et al., 2002). SIRT3 deacetylates and thereby activates the enzymes 
isocitrate dehydrogenase 2 (Idh2) and superoxide dismutase 2 (SOD2), which are involved in 
reducing cellular oxidants, including oxidized glutathione (GSSG) and reactive oxygen 
species (ROS) (Schlicker et al., 2008; Someya et al., 2010; Qiu et al., 2010; Chen et al., 
2011). In addition, SIRT3 promotes alternative energy providing pathways by deacetylating 
and thereby activating central enzymes, which are involved in fatty acid oxidation (3-
Hydroxy-3-methylglutaryl-CoA synthase/HMGCS2, L o n g - c h a i n a c y l - C o A 
dehydrogenase/LCAD, Acetyl-CoA synthetase 2/AceCS2) or the urea cycle (Ornithine 
transcarbamoylase/OTC) (Hallows et al., 2006; Hirschey et al., 2010; Shimazu et al., 2010; 
Hallows et al., 2011).
Recently, it has been discovered that SIRT3 acts as a tumor suppressor, as SIRT3-deficiency is 
sufficient to transform mouse embryonic fibroblasts (MEFs) with Myc or RAS alone to form 
tumors in xenograft models (Kim et al., 2010). This transformation is closely linked to an 
elevation in ROS level, which in turn increases the stability and activity of the transcription 
factor hypoxia inducible factor 1α (HIF-1α). HIF-1α target genes are involved in glucose 
metabolism, angiogenesis, and metastasis (Finley et al., 2011; Bell et al., 2011).
Human SIRT3 is synthesized as a latent inactive preform of 399 amino acids and a predicted 
molecular size of 43.7 kDa. The conserved domain, which is characteristic for all sirtuins, 
stretches from amino acids 139-379. The N-terminal extension contains a mitochondrial 
targeting signal peptide within the first 25 amino acids, which is responsible for the 
characteristic subcellular distribution of the protein. During import of SIRT3 into the 
mitochondrial matrix, the preform is proteolytically cleaved at position 101 and thus 
enzymatically activated (Schwer et al., 2002) (Figure 2). It has been postulated that the 
proteolytically shortened N-terminal region and the C-terminal extension form a module that 
might regulate the access of substrate proteins to the active site (Schlicker et al., 2008).
Presently we know very little about the regulation of SIRT3 function. The biological 
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significance, as summarized briefly above, would suggest strongly that SIRT3 is regulated by 
signaling. Indeed, six phosphorylated serine residues (out of a total of eight possible sites) 
between positions 101 and 118 have been identified in a high-resolution mass spectrometry-
based phosphoproteome analysis (Olsen et al., 2010). But their biological relevance or 
influence on SIRT3 function has not been analyzed yet. These phosphorylation sites are close 
to the mitochondrial cleavage site in the N-terminal extension (Figure 2). Therefore it is 
possible that phosphorylation modulates the enzymatic activity of SIRT3 in mitochondria 
either by regulating the proteolytic cleavage, by influencing the interaction between the N- 
and C-terminal extension, or by regulating the interaction of the N-terminal region with the 
catalytic domain.
1.2.4 SIRT4
SIRT4 is an additional mitochondrial sirtuin (Michishita et al., 2005; Haigis et al., 2006). It 
resides as a soluble protein in the mitochondrial matrix (Ahuja et al., 2007; Nakamura et al., 
2008). Similar to the other sirtuins, SIRT4 is ubiquitously expressed (Michishita et al., 2005; 
Haigis et al., 2006; Ahuja et al., 2007).
Sirt4 knockout mice are viable, fertile and did not display apparent phenotypic abnormalities. 
However, these mice exhibit increased insulin levels when compared with wildtype 
littermates (Haigis et al., 2006). This anomaly points to a function of SIRT4 in the insulin 
producing β-cells of the pancreatic islets. Indeed, SIRT4 negatively regulates glutamate 
dehydrogenase (GDH) via ADP-ribosylation. GDH is a mitochondrial enzyme, which 
catalyzes the conversion of glutamate into α-ketoglutarate in the tricarboxylic acid (TCA) 
cycle and induces insulin secretion (Haigis et al., 2006). A second possible explanation for the 
increased insulin levels measured in Sirt4-deficient mice is that IDE (insulin-degrading 
enzyme) interacts with SIRT4 (Ahuja et al., 2007). IDE regulates insulin levels and SIRT4 
appears to be a negative regulator of this enzyme. Whether this occurs through direct 
interaction or by ADP-ribosylation has not been determined. It is worth pointing out that so 
far no deacetylase activity of SIRT4 has been identified. It remains to be determined whether 
this enzyme is indeed deficient of deacetylase activity or whether this is a reflection of the 
lack of appropriate substrates.
In addition to a function in pancreatic β-cells, SIRT4 is implicated in fatty acid oxidation 
(FAO) in liver cells. A Sirt4 knockdown in primary murine hepatocytes elevates FAO in a 
transcriptional manner. The negative regulation of FAO gene transcription by SIRT4 is 
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mediated by SIRT1, as an additional knockdown of this sirtuin prevents the effect (Nasrin et 
al., 2010). This implies that sirtuins crosstalk with each other.
SIRT4 is expressed as a 314 amino acid long preform with a predicted molecular size of 
35.2 kDa. Analogous to the murine SIRT4 protein sequence the highly conserved sirtuin-typic 
core domain spreads from amino acids 61 to 258 in the human ortholog (Mahlknecht and 
Voelter-Mahlknecht, 2009). The N-terminal extension protruding the conserved domain 
contains a mitochondrial targeting signal peptide within the first ten amino acids. Similar to 
SIRT3, SIRT4 is proteolytically cleaved within the N-terminal extension upon entry into the 
mitochondrial matrix resulting in a 28 amino acids shortened protein (Ahuja et al., 2007) 
(Figure 2). It is not known whether the proteolytic cleavage of SIRT4 influences its enzymatic 
activity, as was reported for SIRT3 (Schwer et al., 2002).
Three phosphorylation sites have been identified in SIRT4 at S255, S261 and S262 in an 
proteomic approach using a phosphopeptide enrichment procedure in combination with data-
dependent neutral loss nano-RPLC-MS2-MS3 analysis (Yu et al., 2007). These findings were 
not further developed to address the biological relevance or influence of these PTMs on 
SIRT4 function.
1.2.5 SIRT5
SIRT5, the third mitochondrial sirtuin, is ubiquitously expressed (Michishita et al., 2005; 
Nakagawa et al., 2009). Very little is known about SIRT5 function. Sirt5 knockout mice 
develop inconspicuously until at least 18 months of age (Lombard et al., 2007). However, 
they exhibit significantly elevated blood ammonia levels compared to wildtype animals after 
calorie restriction or fasting, which are presumably caused by a deregulated urea cycle. In this 
support SIRT5 can deacetylate and activate the carbamoyl phosphate synthetase 1 (CPS1), an 
mitochondrial enzyme of the urea cycle (Nakagawa et al., 2009). It was suggested that 
elevated mitochondrial NAD+ levels during starvation activate SIRT5 and in turn CPS1 is 
activates and initiates the detoxification of excess ammonia under physiological conditions 
(Nakagawa et al., 2009). In addition to its deacetylase activity SIRT5 was very recently 
reported to elicit also NAD+-dependent demalonylase and desuccinylase activities (Jintang 
Du, 2011). In line with thess observations CPS1 succinylation at K1291 is strongly increased 
in Sirt5 knockout mice compared to wildtype littermates. Furthermore Schlicker et al. 
demonstrated in 2008 that SIRT5 can in vitro deacetylate the mitochondrial intermembrane 
space (IMS) protein cytochrome c, which is involved in oxidative metabolism and apoptosis 
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(Schlicker et al., 2008). Up to now, the functional relevance of this observation has not been 
clarified.
SIRT5 is expressed in two distinct transcriptional variants due to alternative splicing, encoding 
proteins with distinct C-terminal regions (Figure 2). The longer transcriptional variant one is 
translated into a 310 amino acid protein with a predicted molecular size of 33.9 kDa. The 
alternative transcriptional variant two is translated into a shorter protein of 299 amino acids 
with a predicted molecular size of 32.7 kDa. The highly conserved core domain spreads from 
amino acids 54 to 256 in both isoforms (Mahlknecht et al., 2006a). Both isoforms can be 
cleaved after the first 36 amino acids at a consensus sequence for the mitochondrial 
processing peptidase (MPP) upon entry into the mitochondrial matrix (Michishita et al., 
2005). Similar to SIRT4 no data are available about a relationship between the N-terminal 
truncation of SIRT5 and its enzymatic activity (Schwer et al., 2002).
Both cleaved SIRT5 isoforms display a mitochondrial localization. There SIRT5 can enter the 
IMS and the mitochondrial matrix (Schlicker et al., 2008). In contrast to the cleaved isoform 2 
(IF2, derived from the shorter splice variant), which seems to reside exclusively in the 
mitochondria, cleaved IF1 is found additionally in the cytoplasm. It appears that the different 
C-termini of the two SIRT5 isoforms are responsible for their distinct subcellular distribution. 
The C-terminal extension of IF2 is rich in hydrophobic amino acids and functions as a 
mitochondrial membrane insertion signal (Matsushita et al., 2011). Presently no post-
translational modifications of SIRT5 are described besides the proteolytic cleavage and thus 
nothing is known about the role of this protein in signaling processes.
1.2.6 SIRT6
SIRT6 is expressed in most tissues (Liszt et al., 2005; Mostoslavsky et al., 2006). It is, similar 
to SIRT1 and SIRT7, predominantly localized in the nucleus (Michishita et al., 2005; Liszt et 
al., 2005), where it associates with the chromatin (Mostoslavsky et al., 2006). A nuclear 
localization signal was discovered between amino acids 345 and 351 in the distal region of the 
C-terminal extension of SIRT6 (Figure 2). This signal is necessary and sufficient for proper 
nuclear localization of the protein (Tennen et al., 2010). In comparison to other sirtuin 
knockout mice, Sirt6-deficient mice display a severe phenotype. Despite  normal development 
for several weeks after birth, these mice die at about one month of age due to degenerative 
processes of multiple organs. These processes include loss of subcutaneous fat and metabolic 
defects displayed by dramatic drops of serum glucose and insulin-like growth factor 1 (IGF1) 
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levels. Additional symptoms are lordokyphosis, colitis, and severe lymphopenia 
(Mostoslavsky et al., 2006). One suggestion is that this phenotype is the consequence of a loss 
of Sirt6-mediated inhibition of NF-κB target gene expression (Kawahara et al., 2009; 
Kawahara et al., 2011). The absence of SIRT6-dependent repression of HIF1α might also 
account for the phenotype (Zhong et al., 2010). Under physiologic conditions SIRT6 interacts 
with these transcription factors and is transported to their target gene promoters where it 
deacetylates H3K9ac or H3K56ac. (Michishita et al., 2008; Kawahara et al., 2009; Yang et al., 
2009). In both cases, the binding of the respective transcription factor to its target gene 
promoters is enhanced in Sirt6-deficient cells due to locally elevated acetylation levels of 
H3K9. Further investigations revealed that upon TNF-α signaling, SIRT6 binds up to 5050 
gene promoters, which are highly enriched for NF-κB, SP1, STAT1/3, ELK1, E2F1, and 
FOXO1/4 binding motifs (Kawahara et al., 2011). Thus SIRT6 appears to have widespread 
activities as a regulator of transcription, in particular of genes whose products are involved in 
glucose and lipid metabolisms.
Moreover SIRT6 seems to be involved in DNA repair and thus in the maintenance of genomic 
integrity. Indeed MEFs derived from Sirt6-deficient mice are more sensitive to irradiation and 
display multiple chromosomal aberrations, i.e. fragmentations, detached centromeres and 
translocations (Mostoslavsky et al., 2006). In addition SIRT6 associates with chromatin in 
response to DNA damage and stabilizes the DNA-dependent protein kinase (DNA-PK) at 
DNA double-strand breaks (DSBs) (McCord et al., 2009). SIRT6 also deacetylates CtIP [C-
terminal binding protein (CtBP) interacting protein] in response to DNA damage, which 
promotes the ability of CtIP to mediate DSB repair by homologous recombination (Kaidi et 
al., 2010). Finally SIRT6 is required for telomere maintenance (Tennen and Chua, 2011). 
Together these findings provide strong evidence for a role of SIRT6 in controlling genomic 
stability.
SIRT6 is expressed as a 355 amino acids long protein with a predicted molecular size of 
39.1 kDa. The sirtuin-typic core domain, which spreads from amino acids 52 to 221 
(Mahlknecht et al., 2006b), is not sufficient to deacetylate H3K9ac or H3K56ac (Tennen et 
al., 2010). For SIRT6 the available evidence suggests that the N-terminal region is essential 
for deacetylase activity as a SIRT6 mutant that lacks the N-terminal regions fails to 
deacetylate H3K9ac or H3K56ac. This is reminiscent of the findings with other sirtuins, 
which require either N- or C-terminal regions to activate catalytic function as described 
above.
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In addition to its deacetylase activity, SIRT6 has been reported to mono-ADP-ribosylate 
substrates. One substrate identified is PARP1/ARTD1, which is activated by SIRT6 (Mao et 
al., 2011). This provides an additional link to genomic stability because ARTD1 is a DNA 
damage sensor and upon activation synthesizes ADP-ribose polymers that are docking sites 
for repair enzymes (Kleine and Luscher, 2009). SIRT6 can also auto-ADP-ribosylate but the 
site of modification and the functional relevance are unclear (Liszt et al., 2005). It remains to 
be elucidated whether the N-terminal extension is essential for the ADP-ribosylation activity 
of SIRT6 as it is for the deacetylase activity. Of note is that besides ADP-ribosylation, two C-
terminal phosphorylation sites at Y294 and SS303 have been discovered in a proteomic 
approach (Dephoure et al., 2008) (Figure 2). It remains to be seen whether these 
phosphorylations influence SIRT6 function.
1.2.7 SIRT7
Of the seven human sirtuins, SIRT7 is the least studied. It is a nuclear protein that is 
concentrated in the nucleoli (Michishita et al., 2005) where it interacts with components of the 
rDNA transcription machinery, like the RNA polymerase I (Pol I) and the rDNA transcription 
factor UBF. SIRT7 positively regulates rDNA transcription (Ford et al., 2006; Grob et al., 
2009). Knockdown of SIRT7 in human cancer cell lines blocks cell proliferation and causes 
apoptosis. This drastic effect implies that SIRT7 is required for cancer cell viability (Ford et 
al., 2006). Further evidence supporting this hypothesis is provided by enhanced SIRT7 
expression levels in breast carcinoma biopsies compared to normal, 'nonmalignant' tissue 
(Ashraf et al., 2006). The tumor suppressor factor p53 is a substrate of SIRT7 and thus this 
sirtuin appears to interfere with p53 function, similar to SIRT1 (Vakhrusheva et al., 2008b). 
Sirt7-knockout mice are viable but suffer from progressive heart hypertrophy, accompanied 
by inflammation and decreased stress resistance, possibly a consequence of altered p53 
activity (Vakhrusheva et al., 2008b; Vakhrusheva et al., 2008a).
SIRT7 is expressed as a 400 amino acids long protein with a predicted molecular size of 
44.9 kDa. The highly conserved core domain spreads from amino acids 107 to 278 (Voelter-
Mahlknecht et al., 2006). Little is known about regulatory mechanisms of the catalytic 
activity of SIRT7. Thus despite the fact that SIRT7 resides in the nucleus, no corresponding 
localization signals have been described so far. However, indirect evidence suggests that 
SIRT7 is phosphorylated during mitosis by a CDK complex, but no sites have been mapped 
nor functional consequences defined (Grob et al., 2009).
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1.3 Cyclin-dependent Kinase 5 (CDK5)
CDK5 is a proline-directed serine/threonine kinase and belongs to the protein family of 
cyclin-dependent kinases (CDKs). It was discovered in 1992 by Lew and colleagues who 
purified the kinase from bovine brain extracts (Lew et al., 1992). In contrast to the initially 
identified CDKs that are regulators of the cell cycle, CDK5 is not regulated by cell cycle-
dependent cyclins and seems not to play a role in the control of cell cycle. CDK5 associates 
with its regulatory subunits p35 or p39, which determine its activity, substrate specificity and 
subcellular localization. Both activators carry an N-terminal myristoylation motif, which 
anchors them at the plasma membrane and the cytoskeleton of the cell periphery. The 
association with peripheral membranes is disrupted by calpain-mediated cleavage of p35/p39 
at the N-terminus. The resulting truncated forms p25/p29 are also able to activate CDK5 but 
they alter its target phosphorylation and subcellular distribution, because they are no longer 
myristylated (Patrick et al., 1999). An alternative mechanism to activate CDK5 is 
phosphorylation. C-Abelson (c-Abl) and Fyn are two kinases, which are reported to 
phosphorylate CDK5 at tyrosine 15 (Y15) and thereby activate kinase activity (Zukerberg et 
al., 2000; Sasaki et al., 2002).
Cdk5 knockout mice die around birth due to severe abnormal brain organization, which is 
explained by neuronal migration defects (Ohshima et al., 1999). In addition, mice lacking p35 
display similar but attenuated defects of the central nervous system (Chae et al., 1997). These 
observations promoted the assumption that CDK5 as well as its activators p35/p39 are neuron 
specific. Indeed, CDK5 is involved in several neuronal processes including neuronal 
migration, axon guidance and synaptic transmission. In this context the best studied CDK5 
substrates are the microtubule-associated protein Tau and the focal adhesion kinase (FAK). 
Consistently, deregulation of CDK5 is part of several pathologic disorders, e.g. AD, PD, and 
amyotrophic lateral sclerosis. In this regard, CDK5 deregulation is often caused by 
neurotoxin-induced cleavage of p35 to p25 (Liebl et al., 2011).
An increasing number of publications provide evidence that CDK5 also plays a role in non-
neuronal tissues, including skeletal muscle, pancreas, leukocytes, glia cells and germ cells. 
CDK5 is involved in differentiation of oligodendrocytes, myocytes and monocytes. 
Furthermore CDK5 promotes secretion, not only in neuronal synapsis, but also of insulin in 
pancreatic β-cells. Consistent with the involvement of CDK5 in neuronal migration and cell 
adhesion, CDK5 also promotes adhesion in keratinocytes. In addition, CDK5 influences 
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transcription by interacting and modulating several transcription factors such as p53, myocyte 
enhancing factor-2 (MEF2) and STAT3 (Lalioti et al., 2010). The latter seems to play a role in 
DNA damage response mediated by CDK5 (Courapied et al., 2010). Initial evidence for a role 
of CDK5 in DNA damage response was provided by Turner et al. in 2008. The group revealed 
that treatment of cells with a PARP1 inhibitor, which provokes DNA damage, is  synthetically 
lethal in combination with the knockdown of CDK5. These findings suggest that CDK5 is 
required for DNA damage checkpoint activation during cell cycle progression (Turner et al., 
2008).
Together with the above-summarized studies implicating SIRT2 in stress response in cells of 
the nervous system the findings suggest that the interaction with SIRT2 and SIRT2 regulation 
by CDK5 may be part of a stress-signaling network.
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1.4 State of research and objectives
SIRT2 is highly expressed in the brain especially in myelin-forming oligodendrocytes (OLs) 
(Li et al., 2007; Southwood et al., 2007) and its expression profile correlates with that of OL 
differentiation markers (Li et al., 2007; Werner et al., 2007; Ji et al., 2011). In mature OLs 
SIRT2 abundantly resides in the myelin sheath surrounding the axon (Southwood et al., 2007) 
but its physiological function in these postmitotic cellular structures remains to be elucidated. 
Luthi-Carter et al. demonstrated recently that SIRT2 positively regulates the transcription 
factor SREBP-2 (sterol response element binding protein 2) thereby promoting cholesterol 
biosynthesis in neurons (Luthi-Carter et al., 2010). Cholesterol influences membrane 
thickness and fluidity and is essential for myelin membrane growth and integrity (Saher et al., 
2005). In contrast, cholesterol is also reported to have a detrimental effect in neurons and 
presents a risk factor in neurodegenerative diseases like AD and PD (Stefani and Liguri, 2009; 
Huang et al., 2011). Consistently, Luthi-Carter et al. reported in 2010 that SIRT2 inhibition 
reduces toxicity of mutant huntingtin by decreasing sterol biosynthesis (Luthi-Carter et al., 
2010). In addition, SIRT2 knockdown or SIRT2 inhibition decreases α-synuclein toxicity, 
which is a hallmark of PD (Outeiro et al., 2007). An alternative explanation for the positive 
effect of SIRT2 downregulation on toxicity of aggregation-prone proteins is its postulated 
implication in macroautophagy (autophagy). Autophagy together with the ubiquitin-
proteasomal system is responsible for elimination of protein-aggregates, which are a feature 
of many neurodegenerative diseases (Madeo et al., 2009). In this regard Zhao and colleagues 
provided evidence that cytoplasmic FOXO1 is required for stress-induced autophagy. FOXO1 
is a transcription factor but its function in autophagy is independent of its gene regulatory 
properties. The authors demonstrated that stress induction disrupts an interaction between 
SIRT2 and FOXO1, which results in increased acetylation of FOXO1. Acetylated FOXO1 in 
turn activates the autophagy-regulating protein Atg7 and thus promotes autophagy (Zhao et 
al., 2010a).
Very little is known about how SIRT2 is regulated both in normal and deregulated cell 
physiology. In this regard phosphorylation of SIRT2 at serine 368/335 (S368/335) and 
S372/335 in its C-terminal extension by p35/CDK5 is especially interesting because similar to 
SIRT2, CDK5 is highly expressed in the brain and its protein levels are upregulated in 
differentiating cells, i.e. OLs (He et al., 2011). Furthermore CDK5 is an important cell cycle 
suppressor in postmitotic neurons (Cicero and Herrup, 2005). Its cell cycle suppressor 
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activities require a nuclear localization of CDK5, which is mediated by an interaction with 
p27 (Zhang et al., 2008). Upon stress, e.g. induced by β-amyloid expression in an AD model, 
association between p27 and CDK5 is disrupted resulting in reduced nuclear CDK5 levels 
(Zhang et al., 2010). Further evidence for CDK5 dysregulation as a component of 
neurodegenerative diseases is provided by accumulation of CDK5 and p25, a p35 cleavage 
product, in Levy bodies of AD patients (Lau and Ahlijanian, 2003).
The aim of this work was to analyze mechanisms that regulate SIRT2 with emphasis on its 
postmitotic function. In regard of regulatory mechanisms that target sirtuin function, PTMs 
play an important role. In sirtuins these occur, as far as analyzed, almost exclusively in the 
regions neighboring the conserved catalytic domain. These modifications influence enzymatic 
activity, intracellular distribution and/or inter- and intramolecular interaction of individual 
sirtuins. I focused my studies on SIRT2 phosphorylation, especially phosphorylation of 
S372/335. On that account I studied CDK5-SIRT2 signaling as both proteins are implicated in 
postmitotic cell physiology. Finally, generation of specific antibodies recognizing S368/335 
will help to monitor SIRT2 regulation in cells.
2. Results and discussion 30
2. Results and discussion
2.1 CDK5 induced mobility shift of SIRT2 is caused by 
phosphorylation
SIRT2 is expressed in two isoforms due to an alternative start codon (Voelter-Mahlknecht et 
al., 2005) and in some cases these differ in their subcellular distribution. Thus Suzuki et al. 
reported in 2007 that only the shorter isoform 2 is present in the myelin-enriched fractions of 
adult mouse brains and Werner et al. observed that only isoform 2 is found in the cytoplasm 
of murine cerebellar granule cells (Suzuki and Koike, 2007; Werner et al., 2007). Both 
heterologously expressed or endogenous SIRT2 isoforms display a characteristic triple band 
pattern in SDS-PAGE, which can be reversed to a single band after phosphatase treatment 
(Dryden et al., 2003; Nahhas et al., 2007). This indicates that phosphorylation reduces the 
mobility of SIRT2 in SDS-PAGE, which is displayed by a shift of the SIRT2-specific band on 
the corresponding Western blots. Mutational analysis revealed that two sites in the C-terminal 
extension of SIRT2 are targets of phosphorylation, namely S368 (S331 in isoform 2) and 
S372 (S335 in isoform 2). Their substitution to an alanine abolishes the mobility shift of 
SIRT2 and results in a single band pattern comparable to the phosphatase treatment 
suggesting that the mobility shift is caused by phosphorylation of these sites (Nahhas et al., 
2007). Interestingly, hyperphosphorylation of SIRT2 at S368/331 and S372/335 is observed in 
cells treated with microtubule inhibitors such as Nocodazole (Nahhas et al., 2007; North and 
Verdin, 2007b). Nocodazole is a synthetic anti-tubulin agent, which reversibly interferes with 
the polymerization of microtubules (Samson et al., 1979). It is often used to arrest cells in 
G2/M phase of the cell cycle as treated cells are unable to form mitotic spindles. Therefore 
hyperphosphorylation of SIRT2 in cells treated with nocodazole implies that SIRT2 is 
phosphorylated in a cell cycle-dependent manner. Indeed, we and others discovered that 
S368/331 is part of a CDK-motif and can be phosphorylated by diverse CDK complexes, such 
as Cyclin B1/CDK1, Cyclin A/CDK2, Cyclin E/CDK2, Cyclin D3/CDK4, and p35/CDK5 
(North and Verdin, 2007b; Pandithage et al., 2008). But synchronization studies with SIRT2 
mutants, in which either S368/331 or S372/335 was substituted by an alanine (single 
phospho-mutants) (Nahhas et al., 2007), indicate that a phosphorylation of the second site, 
S372/335, is actually responsible for the hyperphosphorylation status of SIRT2 observed in 
Nocodazole treated cells. To date, no kinase has been identified, which targets S372/335. An 
alternative effect of Nocodazole treatment is the activation of the spindle assembly 
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checkpoint. Once activated it halts cell cycle progression when mitotic spindle positioning or 
assembly are impaired (Cuschieri et al., 2007). In fact further studies of Inoue and colleagues 
provided evidence that SIRT2 is required for mitotic stress induced cell death mediated by 
spindle checkpoint activation (Inoue et al., 2007; Inoue et al., 2009). However, the expression 
profile of SIRT2 implies a postmitotic function, which is supported by the positive effect of 
SIRT2 inhibition or knockdown on toxicity of neurodegenerative proteins. In this regard I 
focused my studies on SIRT2 phosphorylation by p35/CDK5.
To analyze phosphorylation of SIRT2 by p35/CDK5 I transiently co-expressed p35/CDK5 
with SIRT2 isoform 2 wildtype (wt) and mutants in HEK293 cells. In the SIRT2 mutants each 
or both described phosphorylation sites were substituted by an alanine. Cell lysates were 
subjected to SDS-PAGE and SIRT2 was detected by Western blotting (Figure 4).
Figure 4: Mobility shift of SIRT2 wt and phosphorylation mutants induced by co-expression of p35/CDK5. 
HEK293 cell were transiently transfected with the indicated expression plasmids. After 48 hours cells were 
harvested and lysed in CoIP buffer. SIRT2 was immuno-precipitated with a tag-specific antibody. Immuno-
precipitated SIRT2 and the co-expressed p35/CDK5 complex were detected by Western blotting with tag-specific 
(α-HA, α-GFP) or protein-specific (α-p35) antibodies. Detection of α-tubulin was used as a loading control. 
Small numbers highlight phosphorylation-dependent mobility shift of SIRT2 (1: unphosphorylated, 2: single-
phosphorylated, 3: double-phosphorylated).
Consistent with the literature SIRT2 wt displayed a characteristic triple band pattern (lane 2). 
According to Nahhas et al. the first band represents unphosphorylated SIRT2 whereas 
phosphorylation of either S331 or S335 results in a mobility shift (band 2). 
Hyperphosphorylation of both sites causes an additional shift of the SIRT2 band (band 3) 
(Nahhas et al., 2007). Congruously the single phospho-mutants S331A and S335A form a 
double band pattern (lanes 4, 6) and the double phospho-mutant S331/335A a single band 
(lane 8). Co-expression of p35/CDK5 correlated with a change of the mobility shift pattern of 
SIRT2 wt, as it enhanced the third band and abolished the first band (lane 3). Interestingly, 
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p35/CDK5 co-expression also enhanced the mobility shift of the single phosho-mutant S331A 
(lane 5), in which the CDK5 target site was substituted. The double-phospho-mutant 
S331/335A (lane 9) showed no mobility shift upon p35/CDK5 co-expression.
To confirm that these mobility shifts are caused by phosphorylation, I performed a 
phosphatase assay. Therefor I transiently co-expressed HA-tagged SIRT2 wt or phospho-
mutants with the p35/CDK5 complex in HEK293 cells. After 48 hours I harvested the cells 
and lysed them in CoIP buffer. I immunoprecipitated SIRT2 with a tag-specific antibody and 
subjected the immunoprecipitate to a phosphatase assay. Addition of phosphatase inhibitors or 
mock-treatment served as controls. Afterwards, samples were subjected to SDS-PAGE and 
SIRT2 was detected by Western blotting and a tag-specific antibody (α-HA) (Figure 5). Again 
p35/CDK5 co-expression altered the mobility shift pattern of SIRT2 wt and of the single 
phospho-mutants but had no effect on the double phospho-mutant. Phosphatase treatment but 
not control treatments reversed the band patterns of SIRT2 wt and of the single phospho-
mutants to a single band pattern. The single band pattern of the double phospho-mutant stayed 
unchanged.
Figure 5: Phosphatase assay of SIRT2 wt and phosphorylation site mutants. HEK293 cells were transiently 
transfected with SIRT2- and p35/CDK5-expressing plasmids. Cells were harvested after 48 hours and lysed in 
CoIP buffer containing phosphatase inhibitors. SIRT2 was immunoprecipitated with a tag-specific antibody and 
subjected to a phosphatase (PPase) assay. Afterwards SIRT2 was detected by Western blotting and a tag-specific 
antibody (α-HA). Small numbers highlight phosphorylation-dependent mobility shift of SIRT2 (1: 
unphosphorylated, 2: single phosphorylated, 3: double phosphorylated).
Next, I wanted to test whether I can also induce hyperphosphorylation of endogenous SIRT2. 
Therefor I immunoprecipitated SIRT2 out of CoIP buffer lysates of HEK293 cells, which 
transiently expressed p35/CDK5 (Figure 6). Both immunoprecipitated SIRT2 isoforms 
displayed an altered band pattern upon co-expression of p35/CDK5, which was similar to 
SIRT2 wt in the preceding experiments.
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Figure 6: Mobility shift of endogenous SIRT2. HEK293 cells were transiently transfected as indicated. Cells 
were harvested after 48 hours and transfected cells were selected due to co-expression of CD4. Selected cells 
were lysed in CoIP buffer and endogenous SIRT2 immunoprecipitated with a polyclonal antibody serum (T749). 
Immunoprecipitated SIRT2 was detected by Western blotting with a monoclonal α-SIRT2 antibody (7G5). Both 
SIRT2 isoforms (Isoform 1, 2) were detected. The three phosphorylation-specific isoforms are indicated for the 
two protein isoforms.
These results confirmed that co-expression of CDK5 induces phosphorylation of S368/331. In 
addition CDK5 mediates phosphorylation of SIRT2 at S372/335 and causes 
hyperphosphorylation of SIRT2 as it was observed in Nocodazole-treated cells (Nahhas et al., 
2007). Furthermore SIRT2 is targeted by phosphorylation even without co-expression of 
p35/CDK5 indicated by a prominent second band of endogenous SIRT2 or SIRT2 wt. This 
can be explained by the activity of endogenous CDK-complexes, which are reported to 
phosphorylate SIRT2 at S368/331 (Pandithage et al., 2008), and whose activities are 
indispensable for proliferating cells, such as HEK293 cells.
2.2 Phosphorylation of SIRT2 at S372/335
To further elucidate CDK5 mediated phosphorylation of SIRT2 I tested whether p35/CDK5 
directly phosphorylates SIRT2 at S372/335 as this was already demonstrated for S368/331 
(Pandithage et al., 2008). For that purpose I generated fusion proteins consisting of a GST-tag 
and the C-terminal extension of SIRT2 (sequence in Figure 7a), which contained both 
phosphorylation sites either in a wt conformation (CT wt) or substituted by an alanine (CT-
S331A, -S335A, -S331/335A). Note that this region is common in both SIRT2 isoforms but 
for simplicity the numbering refers to isoform 2 only. I incubated these proteins in the 
presence of radioactively labeled ATP (32P-γ-ATP) with the p35/CDK5 complex, which I 
immunoprecipitated out of transiently transfected HEK293 cells. I used a catalytically 
inactive CDK5 (CDK5-Δcat) mutant as a negative control to exclude unspecific 
phosphorylation of the SIRT2 C-terminal extension by a co-precipitated kinase. A sample 
containing GST instead of a GST-fusion protein was included in the assay to exclude 
unspecific phosphorylations at the GST-tag. After an incubation at 30 °C for 30 minutes the 
samples were subjected to SDS-PAGE and phosphorylation signals were detected via 
autoradiography. Incubation of CT wt with p35/CDK5 but not with p35/CDK5-Δcat produced 
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a radioactive signal corresponding to the GST-fusion protein stained by Coomassie blue. This 
signal was specific for the CT wt as no signal appeared in the GST control sample, which was 
treated in parallel. Furthermore no corresponding phosphorylation signal was detected in the 
samples containing the double phospho-mutant CT-S331/335A or the single phospho-mutant 
CT-S331A. On the other hand incubation of p35/CDK5 with the single phospho-mutant CT-
S335A resulted in a distinct signal corresponding to the GST-tagged C-terminal extension.
Figure 7: Kinase assay with p35/CDK5 and SIRT2 C-terminus (CT). A) Amino acid sequence of the SIRT2-CT 
that was fused to the GST-tag. Numbering according to SIRT2 isoform 2. Phosphorylation sites are indicated. B) 
HEK293 cells were transiently transfected with plasmids expressing HA-tagged CDK5 or a catalytically inactive 
CDK5 mutant (Δcat) and p35. Cells were lysed after 48 hours and p35/CDK5 complexes immunoprecipitated 
with a tag-specific antibody (α-HA) A) Bacterially expressed and purified GST-SIRT2 C-terminus or the 
respective phosphorylation site mutant were incubated with the immunoprecipitated p35/CDK5 complexes and 
radioactively-labeled ATP (32P). Samples were subjected to SDS-PAGE and gels stained with coomassie blue 
(CB). Phosphorylation was detected by autoradiography.
These results confirmed that p35/CDK5 directly targets S331 in SIRT2 but does not 
phosphorylate S335. It is unlikely that phosphorylation of S335 depends on phosphorylation 
of S331 because both single phospho-mutants are phosphorylated upon p35/CDK5 co-
expression in cells. Hence phosphorylation of SIRT2 at S335 upon CDK5 co-expression in 
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cells is most likely mediated by a kinase downstream of p35/CDK5 (Figure 7b).
A putative candidate kinase, which is activated downstream of p35/CDK5, is CDK16. Similar 
to SIRT2, CDK16 is predominantly localized in the cytoplasm and highly expressed in 
terminally differentiated cells of brain and testis (Besset et al., 1999). Furthermore CDK16 
can interact with p35. CDK16 is phosphorylated by p35/CDK5 at S95 and thereby activated 
(Cheng et al., 2002). To test whether CDK16 phosphorylates SIRT2 at S335 I co-expressed 
CDK16 and its activator Cyclin Y with SIRT2 wt and phospho-mutants and monitored the 
SIRT2 mobility shift in a SDS-PAGE gel by Western blotting with tag-specific antibodies as 
described before (Figure 8).
Figure 8: Mobility shift of SIRT2 wildtype (wt) and phosphorylation site mutants induced by co-expression of 
Cyclin Y/CDK16. Experimental procedures as in Figure 4. HCT116 cells served as model cell line and detection 
of transiently expressed proteins was carried out with tag-specific antibodies (α-HA, α-GFP, α-Flag). Tubulin 
was detected as a loading control. Small numbers highlight phospho-specific isoforms (1: unphosphorylated, 2 
single phosphorylated, 3: double phosphorylated).
Similar to p35/CDK5, co-expression of Cyclin Y/CDK16 induced a change of the specific 
band pattern of SIRT2 wt and the single phospho-mutant S331A. The effect was not as strong 
as for p35/CDK5 because despite the occurrence of the third band (wt, lane 3), which 
represents double phosphorylated SIRT2, a subset of SIRT2 remained unphosphorylated, 
indicated by the lowest band. Furthermore co-expression of Cyclin Y/CDK16 had no effect 
on the single phospho-mutant S335A and the double phospho-mutant S331/335A. According 
to these results Cyclin Y/CDK16 co-expression mediates the phosphorylation of SIRT2 at 
S335 but it seems to have no effect on S331 as no enhanced mobility shift of the single 
phospho-mutant S335A occurred. It remains to be elucidated whether Cyclin Y/CDK16 
phosphorylates SIRT2 directly and whether CDK5-mediated phosphorylation of SIRT2 at 
S335 requires CDK16 or vice versa. These questions will be addressed by siRNA experiments 
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and in vitro kinase assays in the future. Furthermore it is possible that phosphorylation of 
SIRT2 at S335 by CDK5 requires association of CDK5 with a different activator, such as p39 
or the cleavage products p25 or p29. In vitro kinase assays using these alternative CDK5 
complexes shall help to study this possibility. 
2.3 α-SIRT2 antibody characterization
To decipher the biological function of SIRT2 phosphorylation at S335 I generated SIRT2-
specific antibodies in a cooperation with E. Kremmer. Therefore I designed a peptide 
comprising 14 amino acids of the SIRT2 C-terminal extension including the phosphorylation 
sites S331 and S335, in which either S335 or both phosphorylation sites were conjugated with 
a phosphate group (Peptide production by PSL GmbH). These peptides were then used to 
immunize rats and mice. Antibody producing B cells of these animals were then fused with 
myeloma cells and the resulting hybridoma cell lines grown in tissue culture. Monoclonal 
antibodies from cell culture supernatants were screened initially in an enzyme-linked 
immunosorbent assay (ELISA) (Antibody production by E.Kremmer). I tested 107 positively 
screened antibody clones for SIRT2 specificity and their ability to detect phosphorylation of 
S331 and S335. These tests included a set of previously described α-SIRT2 antibodies 
generated with a peptide, in which S331 was phosphorylated (Pandithage et al., 2008). I 
wanted to expand their characterization concerning S335 phosphorylation, as both 
phosphorylation sites are situated in close proximity and might interfere with antigen 
recognition.
My tests consisted of two types of assays. First I generated cell lysates of HEK293 cells, 
which transiently expressed either HA-tagged SIRT2 wt or one of the two single phospho-
mutants (S331A or S335A) and p35/CDK5 to induce phosphorylation of S335. Mock-
transfected cells served as negative control. These cell lysates were subjected to SDS-PAGE 
and SIRT2 was detected via Western blot using either a tag-specific antibody (α-HA) or one 
of the antibodies to be analyzed (Figure 9a, c). Comparisons of immuno-reactivities between 
tag-specific and putative protein-specific antibodies allowed identification of SIRT2-specific 
antibody clones (summarized in Table 1). Furthermore antibody clones that detected 
SIRT2 wt specifically but not the phospho-mutant were delineated as phospho-specific. In a 
second screen I controlled phospho-specificity in a phosphatase assay as described before 
(Figure 9b,d).
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Figure 9: Results of selected α-SIRT2 antibody clones tested. To examine the specificity of the monoclonal α-
SIRT2 antibodies HEK293 cells were transiently transfected with HA-tagged SIRT2 wildtype (wt) or single 
phospho-mutant (S331A or S335A) expressing plasmids. Co-expression of the p35/CDK5 complex induced 
phosphorylation of S335 and the corresponding mobility shift in SDS-PAGE. As a negative control cells were 
mock transfected. Cells were harvested after 48 hours and lysed in CoIP-buffer containing phosphatase 
inhibitors. Small numbers highlight phosphorylation-specific isoforms (1: unphosphorylated, 2 single 
phosphorylated, 3: double phosphorylated). A, C) Lysates were subjected to SDS-PAGE and SIRT2 detected by 
Western blotting and a tag-specific or a monoclonal α-SIRT2 antibody. Pictograms on the right illustrate the 
epitopes, which are recognized by the antibodies (green). B, D) SIRT2 was immunoprecipitated with a tag-
specific antibody and subjected to a phosphatase (PPase) assay. PPase inhibitors were included in control 
samples. Afterwards samples were subjected to SDS-PAGE and SIRT2 was detected by Western blotting and a 
monoclonal α-SIRT2 antibody. A, B) Previously described antibody clones (Pandithage et al., 2008). C, D) 
Newly generated antibody clones.
Table 1: List of all positively tested monoclonal SIRT2-specific antibodies. The list displays properties of all 
positively tested α-SIRT2-antibody sera incl. the type species it was generated in and phosphorylation status 
(unphosphorylated “-” or phosphorylated “P”) it is specific for (recognition “+”, no recognition “-”). The asterisk 
marked background detection when using a very low antibody dilution.
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Of nine positively tested antibody clones only the previously described clone 7G5 detected 
SIRT2 independently of phosphorylation at S331 or S335 as it can recognize all three bands 
comparable to the tag-specific antibody. The previously described clone 11H2 recognized 
SIRT2 only when S331 was phosphorylated, even when S335 was also phosphorylated, as it 
recognizes the second band and the third band of SIRT2 wt but displayed no signal for the 
single phospho-mutant S331A. In addition, the 11H2 signal vanished after phosphatase 
treatment and was restored by addition of phosphatase inhibitors verifying its phospho-
specificity. The antibody clones 6B5 and 7F2 were phospho-specific for S331 and S335, 
respectively. But their epitope was masked if the other site was phosphorylated as well. Thus 
they stained only the second band of SIRT2 wt but displayed no signal for the respective 
single phospho-mutant. Phosphatase treatment abolished the signals, whereas phosphatase 
inhibitors restored them at least in part. The newly generated clones 4C4, 1C5 and 11F11 
detected SIRT2 only when both sites were phosphorylated as they only stained the third band 
of SIRT2 wt but not the phospho-mutant (Figure 9 and data not shown). Their signals 
vanished after phosphatase treatment and were restored by addition of phosphatase inhibitors. 
The antibody clone 6H10 recognized SIRT2 only when S331 and S335 were 
unphosphorylated because it only stained the first band of either SIRT2 wt or the single 
phospho-mutant. Furthermore the signal was enhanced by phosphatase treatment and restored 
when phosphatase inhibitors were included in the experiment. Properties of all antibodies 
positively tested are summarized in table 1.
2.4 Function of the SIRT2 C-terminal extension
Next I wanted to elucidate the effect of the C-terminal extension and its modifications on 
SIRT2 function. According to phylogenetic analysis of the sirtuin typic core domain, SIRT2 is 
most closely related to the yeast sirtuin Hst2 and the human sirtuin SIRT3 and more distantly 
to SIRT1 (Figure 1) (Frye, 2000). Similar to SIRT2, Hst2 and SIRT1 contain at least one 
functional nuclear export signal and their subcellular localizations are reported to determine 
their deacetylase activities (Wilson et al., 2006; Tanno et al., 2007). Furthermore Hst2 and 
SIRT1 are shown to form homotrimers. Hst2 trimerization is influenced by its C-terminal 
extension and influences the enzyme's activity (Zhao et al., 2003; Vaquero et al., 2004). 
Schlicker et al. demonstrated in 2008 that a deletion of the C-terminal extension in SIRT3 
increased the deacetylase activity of the enzyme. Based on crystallographic structures the 
authors postulated that the N- and C-terminal extensions of SIRT3 form a module that might 
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regulate access of substrate proteins to the catalytic domain (Schlicker et al., 2008). Finally, 
phosphorylation of SIRT1 can have different effects on its substrate specificity or activity 
dependent on the sites that are targeted (Sasaki et al., 2008b; Zschoernig and Mahlknecht, 
2009).
From these data at least three hypotheses concerning a function of the SIRT2 C-terminal 
extension (CT) are conceivable. First, the CT might regulate the interaction of SIRT2 with 
other proteins including substrates. Second, the CT might modulate activity of the catalytic 
core domain. And third, the CT might be involved in the subcellular distribution of SIRT2.
To test the first hypothesis I studied the interaction of SIRT2 and HDAC6. HDAC6 is a 
class II lysine deacetylase, which is dependent on Zn2+ rather than NAD+. Similar to SIRT2, 
HDAC6 is predominantly localized in the cytoplasm and can deacetylate alpha-tubulin at 
lysine 40 (de Ruijter et al., 2003). Both deacetylases are reported to interact. Nahhas et al. 
demonstrated in 2007 that mutants of SIRT2, in which S331 or S335 are substituted by 
alanines, have no effect on the interaction between SIRT2 and HDAC6 in co-
immunoprecipitations (Nahhas et al., 2007). However, it is not clear whether phosphorylation 
of these sites or the CT in general influences such an interaction. Therefore I cloned a SIRT2 
mutant, in which I deleted the complete CT (SIRT2-ΔCT) and used it for co-
immunoprecipitation studies with HDAC6. I transiently transfected HEK293 cells with 
plasmids encoding ECFP-tagged SIRT2 or SIRT2-ΔCT and co-expressed HA-tagged 
HDAC6. 48 hours after transfection, cells were harvested and lysed in CoIP-buffer. SIRT2 or 
HDAC6 were immunoprecipitated with tag-specific antibodies (α-HA or α-GFP). 
Immunoprecipitates and whole cell lysates were subjected to SDS-PAGE and proteins were 
detected by Western blotting with tag-specific antibodies (α-HA or α-CFP). Tubulin detection 
served as a loading control (Figure 10). Both SIRT2 and the truncated mutant were co-
immunoprecipitated by HDAC6 and conversely, HDAC6 was co-immunoprecipitated by 
SIRT2 wt as well as by SIRT2-ΔCT. These results are consistent with previous experiments of 
Nahhas et al., in which the interaction between SIRT2 and HDAC6 was unaffected by 
substitutions of either phosphorylation site by alanines. These observations suggest that the 
unphosphorylated CT does not influence the interaction between SIRT2 and HDAC6 in cells. 
However, it remains to be elucidated whether phosphorylation of the CT promotes a 
conformational change of SIRT2 that blocks the HDAC6 interaction domain of SIRT2. The 
newly generated SIRT2 antibodies will help to address this question as they can be used to 
clarify, which phospho-specific SIRT2 isoform is co-immunoprecipitated by HDAC6. 
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Furthermore it needs to be investigated whether the binding of an alternative interacting 
protein is influenced by the CT in a similar way.
Figure 10: Interaction between SIRT2 and HDAC6 is independent of the SIRT2 CT in cells. HEK293 cells were 
transfected with HA-tagged HDAC6 or ECFP-tagged SIRT2 wildtype (wt) or a C-terminally truncated mutant 
(ΔCT) expressing plasmids. Cells were harvested after 48 hours and lysed in CoIP-buffer. SIRT2 or HDAC6 
were immunoprecipitated with tag-specific antibodies (α-HA or α-GFP) and precipitates subjected to SDS-
PAGE. Proteins were detected by Western blotting and tag-specific antibodies (α-HA or α-CFP). Whole cell 
lysates (WCL) were subjected to SDS-PAGE and Western blot as expression controls. Tubulin detection served 
as a loading control.
Next I tested the effect of the CT on the catalytic activity of SIRT2. Therefor I incubated GST-
SIRT2 wt or the C-terminally truncated GST-SIRT2-ΔCT fusion protein with commercially 
available purified tubulin in the presence of NAD+. As a control of unspecific deacetylation of 
tubulin, I included a sample with GST in the experiment. After an incubation step for up to 
90 minutes, samples were subjected to SDS-PAGE and either stained by Coomassie blue or 
the tubulin acetylation status was detected via Western blot with a specific antibody for 
acetylated tubulin (Figure 11). The tubulin acetylation status was already markedly reduced 
after 30 minutes of incubation in the samples containing SIRT2 wt as well as SIRT2-ΔCT in 
comparison to the GST control sample. Furthermore tubulin incubated with the truncated 
SIRT2 mutant was deacetylated significantly faster compared to the wt protein. This indicates 
that the unphosphorylated CT has an inhibitory function.
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Figure 11: Tubulin-deacetylation assay with SIRT2. GST-SIRT2 wildtype (wt) or a C-terminally truncated GST-
SIRT2-ΔCT fusion protein were incubated with commercially available purified tubulin in the presence of NAD+ 
for the indicated periods of time (0 to 90 minutes). GST protein was included as a negative control for unspecific 
deacetylation of tubulin. Afterwards samples were subjected to SDS-PAGE and either stained by Coomassie blue 
(CB) or the tubulin acetylation status was detected via Western blot with a specific antibody for acetylated 
tubulin (IB). A) Quantification of three independent experiments. Standard deviations are indicated. Significant 
differences were indicated by an asterisk (two-sided students T-test). B) Western blot (IB) and Coomassie blue 
staining of one experiment.
Unfortunately this assay is not sensitive enough to determine exact Michaelis-Menten kinetics 
of the reactions. However, the results allow the conclusion that the CT interferes with the 
enzymatic activity of SIRT2. Hence posttranslational modifications targeting this part of 
SIRT2 provide the potential to regulate the negative effect of the CT on SIRT2 catalytic 
activity. The results are consistent with previously published data, which demonstrate that 
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phosphorylation of S331 reduces enzymatic activity of SIRT2 (Pandithage et al., 2008). In 
addition the assay provides further evidence that the CT is not involved in ligand binding as it 
is necessary for SIRT2 to be in physical contact with its substrate to remove the acetyl-group. 
Taken together the results of the HDAC6-SIRT2 co-immunoprecipitation and of the 
deacetylation assay point to a putative intramolecular effect of S335 phosphorylation. Further 
studies involving the newly characterized SIRT2 phospho-specific antibodies and more 
sensitive enzymatic assays with SIRT2 phospho-mutants shall help to shed light on the 
signaling pathways that target S335 and its effect on SIRT2 function.
2.5 SIRT2 interferes with CDK5 acetylation
In 2009 Choudhary and colleagues identified 3600 acetylation sites in 1750 proteins using a 
high-resolution mass spectrometry approach. One of these sites was lysine 56 (K56) in CDK5 
(Choudhary et al., 2009). The only other member of the CDK family, which is reported yet to 
be a target of acetylation is CDK9 (Sabò et al., 2008). CDK9 is acetylated by GCN5 and 
P/CAF in the catalytic core domain at lysine 48 (K48), which coordinates ATP binding and 
the phosphotransfer reaction. Hence acetylation of K48 inhibits catalytic activity of CDK9. 
Interestingly K48 is conserved in the CDK family and is located in CDK5 at position 33 
(K33) (Sabò et al., 2008). The previously reported substitution of K33 to a threonine (K33T) 
in CDK5 renders the protein catalytically inactive. This mutant was already used in the kinase 
assays shown before. A third interesting link between GCN5 and the CDK5-SIRT2 signaling 
pathway was recently provided by Conacci-Sorrel et al. in 2010, who demonstrated that 
GCN5 can acetylate α-tubulin, which correlates with muscle differentiation (Conacci-Sorrell 
et al., 2010). These data allow the hypothesis that GCN5 can also acetylate CDK5 providing 
the potential for a feedback loop between SIRT2 and CDK5 as SIRT2 would be a candidate 
deacetylase for CDK5.
To test the hypothesis whether CDK5 was acetylated in our model system as well, I 
transiently transfected HEK293 cells with HA-tagged CDK5- and GCN5-encoding plasmids. 
Besides CDK5 wt I also included two mutants, in which either K33 or K56 were substituted 
by a threonine (K33T) or arginine (K56R). To exclude unspecific acetylation signals, control 
cells were mock-transfected. Cells were harvested and lysed in CoIP-buffer containing 
deacetylase inhibitors after 48 hours. CDK5 was immunoprecipitated with a tag-specific 
antibody. Immunoprecipitates and whole cell lysates were subjected to SDS-PAGE and 
Western blot. Acetylated CDK5 was detected with an antibody specific for acetylated lysines. 
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Tubulin detection served as a loading control (Figure 12a).
Figure 12: SIRT2 reverses GCN5-mediated acetylation of CDK5 at K33 in cells. HEK293 cells were transiently 
transfected with expression plasmids as indicated. After 48 hours cells were harvested and lysed in CoIP-buffer 
containing deacetylase inhibitors. CDK5 was immunoprecipitated with a tag-specific antibody. 
Immunoprecipitates (IP) and whole cell lysates (WCL) were subjected to SDS-PAGE and Western blot. 
Acetylated CDK5 was detected with an antibody specific for acetylated lysines. Tubulin detection served as a 
loading control. A) Acetylation of CDK5 and CDK5 mutants after co-expression of GCN5. B) Effect of SIRT2 
co-expression on GCN5-mediated acetylation of CDK5. The SIRT2-specific inhibitor AGK2 was added to cells 
16 hours prior to lysis.
A CDK5-specific acetylation signal was detected in the samples containing GCN5 and either 
CDK5 wt or CDK5-K56R but no signal occurred in samples containing GCN5 and CDK5-
K33T. Furthermore no acetylation signal was detectable with the Kac-specific antibody for 
CDK5 wt and mutants that were expressed alone. These results indicate that co-expression of 
GCN5 mediates acetylation of CDK5 at K33 in cells. Next, I addressed the question whether 
SIRT2 can deacetylate CDK5. Therefore I repeated the last experiment and additionally co-
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expressed the SIRT2 double phospho-mutant (S331/335A) and a catalytically inactive SIRT2 
mutant (SIRT2-H150Y) to CDK5 wt and GCN5. The double mutant was included in the assay 
to exclude phosphorylation-dependent inhibition of SIRT2 by CDK5. Furthermore I treated 
cells with a specific SIRT2 inhibitor (AGK2) 16 hours prior to cell lysis (Figure 12b). 
Consistent with the last experiment GCN5 co-expression induced a CDK5-specific 
acetylation signal, which was abolished after co-expression of SIRT2-S331/335A and 
enhanced in the sample containing SIRT2-H150Y. Unfortunately, treatment of cells with 
AGK2 did not restore the acetylation signal of CDK5 in the sample containing SIRT2-
S331/335A. But as nicotinamide treatment in a similar experimental outline restored CDK5 
acetylation to a certain extent (data not shown), I conclude that SIRT2 deacetylase activity 
interferes with CDK5 acetylation at least in cells.
To test whether GCN5 acetylates CDK5 directly I performed an in vitro-acetylation assay. 
Therefore I incubated purified GCN5 (kindly provided by M. Hottiger) with the commercially 
available purified p35/CDK5 complex in presence of acetyl-CoA. To test for unspecific 
acetylation a BSA control was included in the assay. Acetyl-transferase activity was tested in 
two different buffer conditions. Buffer A1 contained DTT and EDTA whereas buffer A2 
contained salts such as MgCl2, NaCl2 and ZnCl2. After incubation samples were subjected to 
SDS-PAGE and acetylated CDK5 was detected via Western blot with a specific antibody for 
acetylated lysines. Proteins were detected by Ponceau staining before antibody incubation 
(Figure 13a). An acetylation signal was detected only in the sample containing GCN5 and 
p35/CDK5 just under 35 kDa, which correlates with the predicted molecular size of 33 kDa 
for CDK5. P35 was fused to a GST-tag and should run between 50 and 55 kDa. Furthermore 
the acetylation signal occurs only when the proteins were incubated in buffer A2. The results 
indicate that GCN5 directly acetylates CDK5 in vitro. In a similar approach I tested whether 
other acetyltransferases, such as P/CAF, p300, CBP or TIP60, are also able to acetylate CDK5 
(Figure 13b). P/CAF, which belongs to the same class of lysine acetyltransferases as GCN5 
displayed a similar activity in the assay as GCN5, with preference for buffer A2. CBP and 
p300 induced a slightly different acetylation signal pattern. In both samples a CDK5-specific 
signal was detected with preference for buffer A1. Additionally both enzymes acetylated p35, 
which was indicated by an acetylation signal at about 55 kDa. An additional acetylation signal 
slightly above the 35 kDa mark might be explained by p35 without its GST-tag. To my 
knowledge there are no reports about an acetylation of p35 published yet. 
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TIP60 incubation induced no acetylation signal for CDK5 or p35, neither in buffer A1 nor A2. 
All acetyltransferases tested in Figure 13b displayed an auto-acetylation activity as was 
described previously (Wang and Chen, 2010; Blanco-Garcia et al., 2009; Karanam et al., 
2006) demonstrating their activity under the tested assay conditions. In summary, CDK5 is 
target of acetylation in vitro and in cells. GCN5 mediates acetylation of CDK5 at K33 in cells, 
which provides evidence for an additional acetylation site in CDK5. I did not attain evidence 
for K56 acetylation as was described by Choudhary et al. (Choudhary et al., 2009). This might 
be explained by distinct experimental conditions in my experiments, e.g. the α-Kac antibody 
might not be able to recognize K56ac or the responsible K56 acetyltransferase might not be 
active in the model system used. In vitro acetylation assays with different CDK5 mutants will 
reveal whether the positively tested acetyltransferases specifically acetylate different lysine 
residues in CDK5 or whether they are K33-specific. In further experiments I want to elucidate 
the effect of acetylation on CDK5 activity. Furthermore I want to test whether SIRT2 directly 
deacetylates CDK5. These experiments require production of enzymatically active CDK5 
complexes, which is in progress.
Figure 13: Figure 13: In vitro-acetylation assay of p35/CDK5 with different lysine acetyltransferases. 
Commercially available p35/CDK5 proteins were incubated with baculovirally expressed and purified KATs (M. 
Hottiger) in presence of acetyl-CoA. KAT activity was tested in two different buffers. To exclude unspecific 
acetylation a BSA control was included in the assay. Afterwards samples were subjected to SDS-PAGE and 
acetylated CDK5 was detected via Western blot with a specific antibody for acetylated lysines (α-AcK). A) 
GCN5. Proteins were detected by Ponceau staining before antibody incubation. B) p300, CBP, P/CAF and 
TIP60. Proteins were detected by Coomassie blue (CB) staining.
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3. Conclusions
SIRT2 is expressed in two isoforms due to an alternative start codon (Voelter-Mahlknecht et 
al., 2005) and in some cases these differ in their subcellular distribution. Thus Suzuki et al. 
reported in 2007 that only the shorter isoform 2 is present in the myelin-enriched fractions of 
adult mouse brains and Werner et al. observed that only isoform 2 is found in the cytoplasm 
of murine cerebellar granule cells (Suzuki and Koike, 2007; Werner et al., 2007). Inhibition of 
SIRT2 is reported to reduce neurotoxicity of mutant huntingtin and α-synuclein toxicity, 
which are hallmarks of neurodegenerative Huntington's and Parkinson's disease (Luthi-Carter 
et al., 2010; Outeiro et al., 2007).
Two phosphorylation sites have been identified in SIRT2, which are located in the CT in close 
proximity to each other at S368/331 and S372/335 (Nahhas et al., 2007). S368/331 is part of a 
cyclin-dependent kinase (CDK) recognition motif and has been shown to be a substrate of 
Cyclin B/CDK1, Cyclin E/CDK2, Cyclin A/CDK2, Cyclin D3/CDK4 and p35/CDK5 (North 
and Verdin, 2007b; Pandithage et al., 2008). Phosphorylation of SIRT2 at S368/331 reduces 
its enzymatic activity (Pandithage et al., 2008). Upon mitotic stress induction by nocodazole 
SIRT2 gets hyper-phosphorylated (Nahhas et al., 2007; North and Verdin, 2007b) caused by 
the additional phosphorylation of S372/335 by an unknown kinase. Due to its expression 
profile and implication in neurodegenerative diseases I studied the regulation of SIRT2 by 
CDK5.
Of the CDK complexes that target SIRT2 at S368/331, CDK5 is particularly interesting, as it 
is highly abundant in the brain and its protein levels are upregulated in differentiating cells, 
i.e. oligodendrocytes (He et al., 2011). Furthermore CDK5 is an important cell cycle 
suppressor in postmitotic neurons (Cicero and Herrup, 2005). Its cell cycle suppressor 
activities require a nuclear localization of CDK5, which is mediated by an interaction with 
p27 (Zhang et al., 2008). Upon stress, e.g. induced by β-amyloid accumulation in an 
Alzheimer’s disease (AD) model, association between p27 and CDK5 is disrupted resulting in 
reduced nuclear CDK5 levels (Zhang et al., 2010). Further evidence for CDK5 dysregulation 
as a component of neurodegenerative diseases is provided by accumulation of CDK5 and p25 
in Levy bodies of AD patients (Lau and Ahlijanian, 2003).
Here I confirmed that p35/CDK5 phosphorylates SIRT2 at S331 in cells and in vitro. 
Additionally I demonstrated that p35/CDK5 co-expression mediates phosphorylation of 
SIRT2 at S335. A candidate kinase acting downstream of CDK5 is CDK16, which also 
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induced phosphorylation of SIRT2 at S335 in cells. It is conceivable that CDK5 translocates 
to the cytoplasm in postmitotic cells upon stress induction, e.g. by aggregating proteins, where 
it activates CDK16 and phosphorylates SIRT2 at S331. CDK16 in turn phosphorylates SIRT2 
at S335. It remains to be elucidated how hyper-phosphorylation of SIRT2 affects cells. One 
possible cellular process, which might be activated in this way is autophagy, which is a 
critical process for degradation of protein aggregates. Recently, Zhao and colleagues provided 
evidence that cytoplasmic FOXO1 is required for stress-induced autophagy independent of its 
transcription factor properties in cancer cell lines. They demonstrated that stress induction 
disrupted an interaction between SIRT2 and FOXO1, which resulted in increased levels of 
acetylated FOXO1. Acetylated FOXO1 in turn activated the autophagy-regulating protein 
Atg7 and thus promoted autophagy and cell death (Zhao et al., 2010a). My results support the 
hypothesis that the CT of SIRT2 administrates an inhibitory effect on the catalytic activity of 
SIRT2 rather than ligand binding. Perhaps stress-induced hyper-phosphorylation of SIRT2 
enhances the inhibitory effect of the CT. This would consequently allow an increase in 
acetylated FOXO1 levels and in turn-over rates of protein-aggregates by autophagy. The 
feedback-loop between SIRT2 and CDK5 allows a fine-tuning of this model system. 
Assuming acetylation of CDK5 by GCN5 inhibits its kinase activity as it did with CDK9 
(Sabò et al., 2008), the repressive phosphorylation of SIRT2 would be interrupted. GCN5 is 
already described to respond to stress such as aggregation of misfolded proteins by inducing 
gene transcription (Welihinda et al., 1999). However, it has been reported that GCN5 is also 
found in the cytoplasm of differentiating cell, where it acetylates α-tubulin (Conacci-Sorrell et 
al., 2010). Therefore it is conceivable that cytoplasmic GCN5 is also activated upon stress 
signaling to prevent excessive autophagy induction.
My results provide further knowledge about regulatory mechanisms that target SIRT2 and 
CDK5, two proteins that are involved in postmitotic cell physiology and whose deregulation 
support neurodegeneration. Therefore my results will help to understand the development of 
neurodegeneration, which is important to design new drugs to treat affected patients.
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4. Experimental Procedures
Materials and Methods are described according to standard protocols used in the Institute of 
Biochemistry and Molecular Biology, RWTH Aachen University, and modified regarding 
individual differences in experimental procedures.
4.1 Consumables and reagents
4.1.1 Consumables
Used consumables were purchased from the following companies:
Amersham Biosciences, Ansell, Becton Dickinson, Biometra, Bio-Rad, Biosan, Biotron, 
Biozym, Brand, Braun, Cellstar, Costar, Eppendorf, eBioscience, Falcon, Fisher Scientific, 
Fuji, Gibco BRL, Heidolph, Hirschmann, Integra Biosciences, Komberley-Clark, Kojair, 
Millipore, Nalgene, Nerbe Plus, Omnilab, Rainin, Roth, Sanyo, Sarstedt, Sartorius, Schott 
Duran, Semper med, Siemens, TPP, VWR
4.1.2 Reagents
Used reagents met at least the criteria for the purity standard p.a. and were purchased from the 
following companies:
Amersham Pharmacia Biotech, AppliChem, Bayer, BD Biosciences, Bode, Biometra, Bio-
Rad, Calbiochem, Chroma, Clontech, Eurogentec, Fermentas, Finnzymes, Fluka BioChemika, 
Gibco, Invitrogen, Invivogen, Merck, New England Biolabs, PAA, Pierce, Qiagen, Roche, 
Santa Cruz Biotechnology, Seromed, Serva, Sigma, Zymo Research
Reaction kits
– GeneJETTM Plasmid Miniprep Kit (Fermentas)
– NucleoBond® Xtra Maxi Plus (Macherey-Nagel)
– ZymocleanTM Gel DNA Recovery Kit (Zymo Research)
– ZyppyTM Plasmid Miniprep Kit (Zymo Research)
4.2 Oligonucleotides
The following oligonucleotides were purchased from MWG/Operon or Sigma:
Oligonucleotide Name Sequence: 5' → 3'
CDK5-277-F AGT TGC AAT GGT GAC CTC GAT CCT
CDK5-279-F TTG CAA TGG TGA CCT CGA TCC TGA
CDK5-attB1-F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC GAT 
GCA GAA ATA CGA GAA A
CDK5-attB2-R ACC CAG CTT TCT TGT ACA AAG TGG TCC CCC CTA 
GGG CGG ACA GAA GTC G
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Oligonucleotide Name Sequence: 5' → 3'
CDK5-K33T-F CTC ATG AGA TCG TGG CTC TGA CGC GGG TGA GGC
CDK5-K33T-R AGC CTC ACC CGC GTC AGA GCC ACG ATC TCA TGA G
CDK5-K56R-F CGG GAG ATC TGC CTA CTC AGG GAG CTG AAG
CDK5-K56R-R CTT CAG CTC CCT GAG TAG GCA GAT CTC CCG
FOXO1-attB1-F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAT 
GGC CGA GGC GCC TCA GGT GGT
FOXO1-attB2-R GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TCA 
GCC TGA CAC CCA GCT ATG TG
FOXO1-sh#1_1 GAT CCC CGC AAT GAT GAC TTT GAT AAC TGC TTC CTG 
TCA CAG TTA TCA AAG TCA TCA TTG CTT TTT GGA AA
FOXO1-sh#1_2 AGC TTT TCC AAA AAG CAA TGA TGA CTT TGA TAA 
CTG TGA CAG GAA GCA GTT ATC AAA GTC ATC ATT 
GCG GG
FOXO1-sh#2_1 GAT CCC CGG ACA ATA AGT CGA GTT ATG GGC TTC CTG 
TCA CCC ATA ACT CGA CTT ATT GTC CTT TTT GGA AA
FOXO1-sh#2_2 AGC TTT TCC AAA AAG GAC AAT AAG TCG AGT TAT 
GGG TGA CAG GAA GCC CAT AAC TCG ACT TAT TGT 
CCG GG
FOXO1-sh#3_1 GAT CCC CGA GTT ATG GAG GTA TGA GTC AGC TTC 
CTG TCA CTG ACT CAT ACC TCC ATA ACT CTT TTT GGA 
AA
FOXO1-sh#3_2 AGC TTT TCC AAA AAG AGT TAT GGA GGT ATG AGT 
CAG TGA CAG GAA GCT GAC TCA TAC CTC CAT AAC 
TCG GG
FOXO1-sh#4_1 GAT CCC CGG TAT GAG TCA GTA TAA CTG TGC TTC CTG 
TCA CAC AGT TAT ACT GAC TCA TAC CTT TTT GGA AA
FOXO1-sh#4_2 AGC TTT TCC AAA AAG GTA TGA GTC AGT ATA ACT GTG 
TGA CAG GAA GCA CAG TTA TAC TGA CTC ATA CCG GG
HDAC6-1614-F CTG TCA CAG TGC TGA GTA CGT
HDAC6-2552-F GTC ACC AAG AAG GCA CCC CAA
HDAC6-832-F TAC GAG CAG GGT AGG TTC T
HDAC6-attB1-F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC TAT 
GAC CTC AAC CGG CCA GGA TTC C
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Oligonucleotide Name Sequence: 5' → 3'
HDAC6-attB2-R GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC CTT 
AGT GTG GGT GGG GCA TAT CCT C
hSIRT2-560-R AGT GTG ATG TGT AGA AGG TGC CGT
p35-attB1-F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT GAT 
GGG CAC GGT GCT GTC CCT GTC TC
p35-attB2-R GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TCA 
CCG ATC CAG GCC TAG GAG GAG C
SIRT2-CT-attB1-F GGG GAC AAG TTT GTA CAA AAA AGC AGG CTG GGC 
GGG GGT CCC CAA CCC CAG CAC
SIRT2-CT-attB2-R GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA 
CTG GGG TTT CTC CCT CTC TGT
SIRT2-ΔATG-F ACA AAA AAG CAG GCT ACG ACT TCC TGC GGA ACT T
SIRT2-ΔATG-R AAG TTC CGC AGG AAG TCG TAG CCT GCT TTT TTG T
SIRT2-ΔG320-F AGA TGC CCA GTC GTA GGC GGG GGT CCC C
SIRT2-ΔG320-R GGG GAC CCC CGC CTA CGA CTG GGC ATC T
SIRT2-H150Y-STUI-F GGA GGC CTA CGG CAC CTT CTA CAC ATC ACA C
SIRT2-H150Y-STUI-R GTG TGA TGT GTA GAA GGT GCC GTA GGC CTC C
SIRT2-S331/335A-F GCC CCC AAG AAG GCC CCG CCA CCT
SIRT2-S331/335A-F CAA CCC CAG CAC TTC AGC TGC CCC CAA GAA
SIRT2-S331/335A-R AGG TGG CGG GGC CTT CTT GGG GGC
SIRT2-S331/335A-R TTC TTG GGG GCA GCT GAA GTG CTG GGG TTG
SIRT2-S331A-PstI-F CCC AGC ACT TCT GCA GCC CCC AAG AAG TCC CC
SIRT2-S331A-PstI-R GGG GAC TTC TTG GGG GCT GCA GAA GTG CTG GG
SIRT2-S331E-F CAA CCC CAG CAC TTC AGC TGA GCC CAA GAA GGA 
GCC G
SIRT2-S331E-R CGG CTC CTT CTT GGG CTC AGC TGA AGT GCT GGG 
GTT G
SIRT2-S335A-F TTC CCC CAA GAA GGC CCC GCC ACC TG
SIRT2-S335A-R CAG GTG GCG GGG CCT TCT TGG GGG AA
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Oligonucleotide Name Sequence: 5' → 3'
SIRT2-S335E-F AGC TTC CCC CAA GAA GGA GCC GCC ACC TGC CAA G
SIRT2-S335E-R CTT GGC AGG TGG CGG CTC CTT CTT GGG GGA AGC T
SIRT2-sh#3_1 GAT CCC CGT CGC AGA GTC ATC TGT TTT TCA AGA 
GAA AAC AGA TGA CTC TGC GAC TTT TTG GAA A
SIRT2-sh#3_2 AGC TTT TCC AAA AAG TCG CAG AGT CAT CTG TTT TCT 
CTT GAA AAA CAG ATG ACT CTG CGA CGG G
SIRT2-sh#4_1 GAT CCC CCA TCC ACC GGC CTC TAT GAT TCA AGA GAT 
CAT AGA GGC CGG TGG ATG TTT TTG GAA A
SIRT2-sh#4_2 AGC TTT TCC AAA AAC ATC CAC CGG CCT CTA TGA TCT 
CTT GAA TCA TAG AGG CCG GTG GAT GGG G
4.3 Plasmids
4.3.1 Cloning vectors/Gateway entry vectors
Plasmid name Description
pDONR/Zeo This vector allows for the recombination of attB-PCR products 
into its attP1 and attP2 sites replacing the Gateway cassette con-
taining the negative selective ccdB gene. M13 priming sites allow 
sequencing of the cloned PCR product in both directions. The 
EM7 promoter drives expression of the Zeocin resistance genes 
used for selection in E. coli. rrnB T1 and T2 transcription termin-
ators protect the cloned gene from expression by vector-encoded 
promoters (from Invitrogen).
pDONR/Zeo-CDK5 This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and GW-pHA-CDK5 (F. Flick).
pDONR/Zeo-CDK5-
K33T
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and GW-pHA-CDK5-K33T (F. Flick).
pDONR/Zeo-CDK5-
K56R
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and GW-pHA-CDK5-K56R (F. Flick).
pDONR/Zeo-FOXO1 This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product of full length human 
FOXO1 cDNA amplified from pcDNA3-Flag-FOXO1 
(N. Schall).
PDONR/Zeo-HDAC6 This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product of full length human 
HDAC6 cDNA amplified from pcDNA3-HDAC6-Flag (F. Flick).
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Plasmid name Description
pDONR/Zeo-SIRT2 This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and GW-pHA-SIRT2 (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and GW-pHA-SIRT2-ΔATG (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-H150Y
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-H150Y-
STUI-F and SIRT2-H150Y-STUI-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S331/335A
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG-
S331A by site-directed mutagenesis using the primers SIRT2-
S335A-F and SIRT2-S335A-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S331/335E
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG-
S335E by site-directed mutagenesis using the primers SIRT2-
S331E-F and SIRT2-S331E-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S331A
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-S331A-
PstI-F and SIRT2-S331A-PstI-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S331E
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-S331E-F 
and SIRT2-S331E-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S335A
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-S335A-F 
and SIRT2-S335A-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-S335E
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-S335E-F 
and SIRT2-S335E-R (F. Flick).
pDONR/Zeo-SIRT2- 
ΔATG-ΔG320
This entry vector was obtained from pDONR/Zeo-SIRT2-ΔATG 
by site-directed mutagenesis using the primers SIRT2-ΔG320-F 
and SIRT2-ΔG320-R (F. Flick).
pDONR/Zeo-SIRT2-
CT
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2 (F. Flick).
pDONR/Zeo-SIRT2-
CT-S331/335A
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-S331/335A (F. Flick).
pDONR/Zeo-SIRT2-
CT-S331/335E
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-ΔATG-S331/335E (F. Flick).
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Plasmid name Description
pDONR/Zeo-SIRT2-
CT-S331A
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-S331A (F. Flick).
pDONR/Zeo-SIRT2-
CT-S331E
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-ΔATG-S331E (F. Flick).
pDONR/Zeo-SIRT2-
CT-S335A
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-S335A (F. Flick).
pDONR/Zeo-SIRT2-
CT-S335E
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering the last 33 amino 
acids of GW-pHA-SIRT2-ΔATG-S335E (F. Flick).
pDONR/Zeo-SIRT2-
ΔG320,
pDONR/Zeo-SIRT2-
H150Y,
pDONR/Zeo-SIRT2-
S331A,
pDONR/Zeo-SIRT2-
S335A,
pDONR/Zeo-SIRT2-
S331/335A
These entry vectors were created by a Gateway BP reaction with 
pDONR/Zeo and the corresponding GW-pHA vectors (F. Flick).
pDONR201 This vector allows for the recombination of attB-PCR products 
into its attP1 and attP2 sites replacing the Gateway cassette con-
taining the negative selective ccdB gene. attP priming sites allow 
sequencing of the cloned PCR product in both directions. It con-
tains a Kanamycin resistance gene used for selection in E. coli. 
rrnB T1 and T2 transcription terminators protect the cloned gene 
from expression by vector-encoded promoters (from Invitrogen).
pDONR201-CDK5 This entry vector was created by a Gateway BP reaction with 
pDONR201 and an attB-PCR product of full length CDK5 ampli-
fied from cDNA of SY5Y neuroblastoma cells (R. Pandithage).
pDONR201-SIRT2 This entry vector was created by a Gateway BP reaction with 
pDONR201 and an attB-PCR product of full length cDNA of 
SIRT2 isoform 2. The plasmid pLafmid-BA-SIRT2 was used as 
template for the attB-PCR reaction (R. Pandithage).
pDONR201-SIRT2- 
ΔATG
This entry vector was obtained from pDONR201-SIRT2 by site-
directed mutagenesis using the primers SIRT2-ΔATG-F and 
SIRT2-ΔATG-R (F. Flick).
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Plasmid name Description
pDONR201-SIRT2-
H150Y
This entry vector was obtained from pDONR201-SIRT2 by site-
directed mutagenesis using the primers SIRT2-H150Y-STUI-F 
and SIRT2-H150Y-STUI-R (R. Pandithage).
pDONR201-SIRT2-
S331/335A
This entry vector was obtained from pDONR201-SIRT2-S335A 
by site-directed mutagenesis using the primers SIRT2-
S331/335A-F and SIRT2-S331/335A-R (F. Flick).
pDONR201-SIRT2-
S331A
This entry vector was obtained from pDONR201-SIRT2 by site-
directed mutagenesis using the primers SIRT2-S331A-PstI-F and 
SIRT2-S331A-PstI-R (R. Pandithage).
pDONR201-SIRT2-
S331E
This entry vector was obtained from pDONR201-SIRT2 by site-
directed mutagenesis using the primers SIRT2-S331E-F and 
SIRT2-S331E-R (R. Pandithage).
pDONR201-SIRT2-
S335A
This entry vector was obtained from pDONR201-SIRT2 by site-
directed mutagenesis using the primers SIRT2-S335A-F and 
SIRT2-S335A-R (F. Flick).
pLafmid-BA-SIRT2 The vector was purchased from RZPD, Berlin and encodes the 
clone IMAGp998N11146q2, which encompasses the full length 
cDNA of human SIRT2 isoform 2. According to sequencing ana-
lysis the cDNA sequence was identical to the sequence described 
by Ashfar and Murnane (Afshar and Murnane, 1999).
pSuper This vector contains the PolIII promoter of H1 and drives the ex-
pression of shRNAs when appropriate oligonucleotides are inser-
ted in BglII/HindIII sites (R. Lilischkis).
4.3.2 Prokaryotic expression plasmids
Plasmid name Description
GW-pGST This vector is derived from pGEX-4T-2 (GE Healthcare), which 
was made compatible with the Gateway system by insertion of 
the Gateway cassette Reading frame A (RfA) into the MCS. It al-
lows for the IPTG-inducible gene expression of an N-terminally 
GST-tagged protein under control of a tac promoter and the lac 
operator (R. Lilischkis).
GW-pGST-SIRT2-CT, 
(S331A), (S335A), 
(S331/335A), (S331E), 
(S335E), (S331/335E)
These vectors were created by a LR reaction with GW-pGST and 
the corresponding pDONR/Zeo entry vectors (F. Flick).
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Plasmid name Description
GW-pGST-SIRT2-
ΔATG, (S331A), 
(S335A), (S331/335A), 
(S331E), (S335E), 
(S331/335E), (ΔG320), 
(H150Y)
These vectors were created by a LR reaction with GW-pGST and 
the corresponding pDONR/Zeo entry vectors (F. Flick).
4.3.3 Eukaryotic expression plasmids
Plasmid name Description
GW-pBac-GST This vector was derived from pVL1392 (BD Bioscience) and 
made compatible with the Gateway system by insertion of the 
Gateway cassette Reading frame C1 (RfC1). It is a Baculovirus 
Transfer Vector that drives the gene expression of GST-fusion 
proteins under the polyhedrin promoter of AcNPV (R. Pan-
dithage).
GW-pBac-GST-CDK5 This vector was created by a LR reaction with GW-pBAC-GST 
and the corresponding pDONR/Zeo entry vector (N. Schall).
GW-pBS-CassA-T3 This vector was derived from pBluscript II KS+ and made com-
patible with the Gateway system by insertion of the Gateway 
cassette Reading frame A (RfA) into the EcoRV site. It drives the 
in vitro transcription from the T3 promoter (R. Lilischkis).
GW-pBS-CassA-T3-
CDK5
This vector was created by a LR reaction with GW-pBS-Cas-
sA-T3 and the corresponding pDONR/Zeo entry vector 
(F. Flick).
GW-pBS-CassA-T3-
FOXO1
This vector was created by a LR reaction with GW-pBS-Cas-
sA-T3 and the corresponding pDONR/Zeo entry vector 
(N. Schall).
GW-pBS-CassA-T3-
HDAC6
This vector was created by a LR reaction with GW-pBS-Cas-
sA-T3 and the corresponding pDONR/Zeo entry vector (D. Ot-
ten).
GW-pcDNA5/FRT/TO This vector was derived from pcDNA5/FRT/TO and made com-
patible with the Gateway system by insertion of the Gateway 
cassette Reading frame A (RfA) into the HindIII site (A. Forst).
GW-pcDNA5/FRT/TO-
SIRT2, (S331A), 
(S335A), (S331/335A), 
(S331E), (S335E), 
(S331/335E), (ΔG320), 
(H150Y)
These vectors were created by a LR reaction with GW-
pcDNA5/FRT/TO and the corresponding pDONR/Zeo entry vec-
tors (F. Flick).
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Plasmid name Description
GW-pECFP The vector pECFP was made compatible with the Gateway sys-
tem by insertion of the Gateway cassette Reading frame C1 
(RfC1) into the SmaI site. It allows for the gene expression of N-
terminally ECFP-tagged proteins (K. Montzka).
GW-pECFP-CDK5, 
(K33T), (K56R)
These vectors were created by a LR reaction with GW-pECYFP 
and the corresponding pDONR/Zeo entry vectors (F. Flick).
GW-pECFP-SIRT2-
ΔATG, (S331A), 
(S335A), (S331/335A), 
(S331E), (S335E), 
(S331/335E), (ΔG320), 
(H150Y) 
These vectors were created by a LR reaction with GW-pECYFP 
and the corresponding pDONR/Zeo entry vectors (F. Flick).
GW-pHA This vectors allows for the gene expression of N-terminally HA-
tagged proteins in eukaryotic cells under control of a strong 
CMV promoter (Matthias et al., 1989). The vector contains the 
pSP65 plasmid sequences, a human CMV promoter/enhancer, the 
translation initiation region from the HSV thymidine kinase, the 
splicing and polyadenylation signals from the rabbit ß-globin 
gene and the SV40 origin of replication. It was made compatible 
with the Gateway system by insertion of the Gateway cassette 
Reading frame C1 (RfC1) into the SmaI site (R. Lilischkis).
GW-pHA-CDK5 This vector was created by a LR reaction with GW-pHA and the 
corresponding pDONR201 entry vector (R. Pandithage).
GW-pHA-CDK5-K33T This vector was obtained from GW-pHA-CDK5 by site-directed 
mutagenesis using the primers CDK5-K33T-F and CDK5-K33T-
R (F. Flick).
GW-pHA-CDK5-K56R This vector was obtained from GW-pHA-CDK5 by site-directed 
mutagenesis using the primers CDK5-K56R-F and CDK5-K56R-
R (F. Flick).
GW-pHA-HDAC6 This vector was created by a LR reaction with GW-pHA and the 
corresponding pDONR/Zeo entry vector (D. Otten).
GW-pHA-SIRT2-
S335A,
GW-pHA-SIRT2-
S331/335A
These vectors were created by a LR reaction with GW-pHA and 
the corresponding pDONR201 entry vectors (F. Flick).
GW-pHA-SIRT2-
ΔATG
This vector was created by a LR reaction with GW-pHA and the 
corresponding pDONR201 entry vector (F. Flick).
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Plasmid name Description
GW-pHA-SIRT2-
ΔATG, (S331A), 
(S335A), (S331/335A), 
(S331E), (S335E), 
(S331/335E), (ΔG320), 
(H150Y)
These vectors were created by a LR reaction with GW-pHA and 
the corresponding pDONR/Zeo entry vectors (F. Flick).
GW-pHA-SIRT2-
ΔG320
This vector was obtained from GW-pHA-SIRT2 by site-directed 
mutagenesis using the primers SIRT2-ΔG320-F and SIRT2-
ΔG320-R (A. Wolf).
GW-pHA-SIRT2, 
(H150Y), (S331A)
These vectors were created by a LR reaction with GW-pHA and 
the corresponding pDONR201 entry vectors (R. Pandithage).
pBabe Puro This is a retroviral mammalian expression vector driving the ex-
pression of a puromycin resistance gene under the control of a 
SV40 early promoter (Morgenstern and Land, 1990).
pBluescript II KS+ This vector is designed for DNA cloning, didesoxy-DNA sequen-
cing, in vitro mutagenesis and in vitro transcription. It contains 
the intergenic region of phage f1; the pMB1 replicon responsible 
for the replication of the vector; the bla-gene, coding for β-
lactamase, that confers resistance to ampicillin and lacZ, the 5’-
terminal part of the lacZ gene encoding the N-terminal fragment 
of β-galactosidase (from Fermentas).
pcDNA3-Flag-FOXO1 This vector was obtained from the pcDNA3-Flag backbone vec-
tor by inserting full length human FOXO1 cDNA between the 
BamH1 and XbaI sites and drives the mammalian gene expres-
sion of N-terminally Flag-tagged FOXO1 from a CMV-promoter. 
It contains an Ampicillin resistance gene used for selection in E. 
coli (from Addgene).
pcDNA3-HDAC6-Flag This vector was obtained from the pcDNA3.1+ backbone vector 
by inserting full length human HDAC6 cDNA at the Not1 site 
and it drives the mammalian gene expression of C-terminally 
Flag-tagged HDAC6 from a CMV-promoter. Furthermore it con-
tains an Ampicillin resistance gene used for selection in E. coli 
(from Addgene).
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Plasmid name Description
pcDNA5/FRT/TO This vector is a 5.1 kb inducible gene expression vector designed 
for usage with the Flp-In-T-REx-System from Invitrogen. It fea-
tures a CMV-promoter for high level tetracycline-regulated ex-
pression of the gene of interest in a wide range of mammalian 
cells; a multiple cloning site with 10 unique restriction sites to fa-
cilitate cloning of the gene of interest; a FLP Recombination Tar-
get (FRT) site for Flp recombinase-mediated integration of the 
vector into the Flp-In-T-REx-host cell line and a Hygromycin 
resistance gene for selection of stable cell lines (from 
Invitrogen).
pCMV-myc-p35 This vector drives the gene expression of the myc-tagged p35 
protein in mammalian cells from a CMV promoter (R. Pan-
dithage).
pEGFP-Tubulin This vector drives the gene expression of the EGFP-tubulin fu-
sion protein in mammalian cells. The protein incorporates dir-
ectly into microtubules and thereby allows the observation of mi-
crotubules in living or fixed cells by fluorescence microscopy. 
The vector was used as a control for transfection efficiency (from 
BD Bioscience/Clontech).
pEQ176P2 This vector was routinely used for control transfections for 
CMV-containing vectors if the respective backbone vector for the 
transfected plasmid was not available. It is derived from 
pEQ176, which drives expression of the ß-galactosidase gene un-
der control of a CMV promoter. Most of the cDNA encoding ß-
galactosidase was cut out by a PvuII restriction digest 
(J. Lüscher-Firzlaff).
pSuper r Ash #5 false This vector drives the gene expression from the histone H1 PolIII 
promoter of a non-functional shRNA targeted against the Ash2 
mRNA. This vector was routinely used for control transfections 
for PolIII promoter-containing vectors (J. Lüscher-Firzlaff).
pSuper-sh-
FOXO1#1,2,3,4
These vectors were derived from pSuper by insertion of the hy-
bridized oligonucleotides sihSIRT2#3,4 between the BglII and 
HindIII sites. They drive the gene expression of shRNAs de-
signed for targeting the human FOXO1 mRNA (F. Flick).
pSuper-sh-hSIRT2#3,4 These vectors were derived from pSuper by insertion of the hy-
bridized oligonucleotides sihSIRT2#3,4 between the BglII and 
HindIII sites. They drive the gene expression of shRNAs de-
signed for targeting the human SIRT2 mRNA (F. Flick).
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4.4 Antibodies
Antibody name Description
α-acetylated-Tubulin
(6-11B-1)
Monoclonal mouse IgG2b antibody that recognizes an epitope loc-
ated on α-tubulin within four residues of K40 when this amino 
acid is acetylated. It is raised against acetylated tubulin from the 
outer arm of Strongylocentrotus purpuratus (sea urchin) (Sigma).
α-alpha-Tubulin
(B-5-1-2)
Monoclonal mouse IgG1 antibody that recognizes an epitope loc-
ated at the C-terminal end of the α-tubulin isoform in a variety of 
organisms. It is raised against Sarkosyl-resistant ribbons from 
Strongylocentrotus purpuratus (Sea Urchin) sperm axonemes 
(Sigma).
α-GFP (JM-3999-100) Polyclonal rabbit antibody, that recognizes the wildtype Green 
Fluorescence protein (GFP) from the pacific jellyfish, Aequorea 
victoria and its variants EGFP and EBFP, etc., even though it is 
introduced into unrelated recombinant proteins by “epitope tag-
ging” (MBL).
α-GFP (9F9-F9) Monoclonal mouse IgG2a antibody that recognizes the Green 
Fluorescence protein (GFP) and its variants rGFP and eGFP, even 
though GFP is introduced into unrelated recombinant proteins by 
“epitope tagging”. The antibody was raised against a GST-GFP 
fusion protein corresponding to the full length amino acid 
sequence (246 aa) derived from the jellyfish Aequorea victoria 
(Rockland).
α-GST (6G9) Monoclonal rat IgG2a antibody recognizing Glutathione S-Trans-
ferase (GST) from Schistosoma japonicum, even though it is in-
troduced into unrelated recombinant proteins by “epitope tag-
ging”. It was raised against a GST-fusion protein (E. Kremmer).
α-HA (3F10) Monoclonal rat IgG1 antibody that recognizes the HA peptide se-
quence (YPYDVPDYA) derived from the influenza hemagglutin-
in protein, even when the HA peptide is introduced into unrelated 
recombinant proteins by “epitope tagging” (Roche).
α-mouse IgG + IgM 
(H+L) HRP-conjugated 
(115-036-068)
Horseradish Peroxidase conjugated secondary antibody from 
goat recognizing the heavy and light chains of mouse IgG and 
IgM antibodies (Jackson Immuno Research).
α-rabbit IgG (H+L) 
HRP-conjugated (111-
035-140)
Horseradish Peroxidase conjugated secondary antibody from 
goat recognizing the heavy and light chains of rabbit IgG anti-
bodies (Jackson Immuno Research).
α-rat IgG + IgM (H+L) 
HRP-conjugated (112- 
035-068)
Horseradish Peroxidase conjugated secondary antibody from 
goat recognizing the heavy and light chains of rat IgG and IgM 
antibodies (Jackson Immuno Research).
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Antibody name Description
α-SIRT2 (11F11) Monoclonal rat IgG antibody recognizing SIRT2 when both S331 
and S335 are phosphorylated. It was raised against a C-terminal 
SIRT2 peptide, which was phosphorylated at S335 
(E. Kremmer).
α-SIRT2 (11H2) Monoclonal rat IgG antibody recognizing SIRT2 when S331 is 
phosphorylated. It was raised against a C-terminal SIRT2 pep-
tide, which was phosphorylated at S331 (E. Kremmer).
α-SIRT2 (1C5) Monoclonal rat IgG antibody recognizing SIRT2 when both S331 
and S335 are phosphorylated. It was raised against a C-terminal 
SIRT2 peptide, which was phosphorylated at S331 and S335 
(E. Kremmer).
α-SIRT2 (3C8) Monoclonal rat IgG antibody recognizing SIRT2 when S335 is 
not phosphorylated. It was raised against a C-terminal SIRT2 
peptide, which was phosphorylated at S331 (E. Kremmer).
α-SIRT2 (4C4) Monoclonal mouse IgG1 antibody recognizing SIRT2 when S331 
and S335 are phosphorylated. It was raised against a C-terminal 
SIRT2 peptide, which was phosphorylated at S331 and S335 
(E. Kremmer).
α-SIRT2 (6B5) Monoclonal rat IgG antibody recognizing SIRT2 when S331 is 
phosphorylated and S335 is not phosphorylated. It was raised 
against a C-terminal SIRT2 peptide, which was phosphorylated at 
S331 (E. Kremmer).
α-SIRT2 (6H10) and 
(7F2)
Monoclonal mouse IgG antibodies recognizing SIRT2 when 
S331 is not phosphorylated. It was raised against a C-terminal 
SIRT2 peptide, which was phosphorylated at S335 
(E. Kremmer).
α-SIRT2 (7G5) Monoclonal rat IgG antibody recognizing SIRT2 independent of 
phosphorylation at S331 or S335. It was raised against a C-ter-
minal SIRT2 peptide, which was phosphorylated at S331 
(E. Kremmer).
α-SIRT2 T749 Polyclonal rabbit antiserum recognizing SIRT2 (E. Kremmer).
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4.5 Work with nucleic acids
4.5.1 Enzymatic manipulation of plasmid DNA
10x “Magic” buffer 200 mM Tris Cl pH 7.5
700 mM NaCl
200 mM KCl
100 mM Magnesium chloride
0.5 mM Spermine
0.125 mM Spermidine
Restriction endonucleases recognize short DNA sequences and cleave double-stranded DNA 
at specific sites within or adjacent to the recognition sequence. In this work restriction digests 
were used to identify plasmids and to transfer restriction fragments between plasmids.
Restriction enzymes and buffers were purchased from Fermentas and used according to 
manufacturer's instructions in a 20 µl reaction volume with 0.5 µl of each restriction enzyme 
used and 2 µl of the appropriate 10x buffer. Reactions were incubated for 1 hour to over-night 
at the appropriate temperature, in general 37 °C. Double digests were transformed in magic 
buffer.
A thermosensitive alkaline phosphatase FastAP (Fermentas) was used to dephosphorylate 
terminal 5' phosphates according to manufacturer's instructions.
DNA was ligated using T4 DNA ligase (Fermentas). Sticky-end ligations were carried out for 
1-2 hours at room temperature. For blunt-end ligations, 5 % PEG2000 was included in the 
reaction, and the reaction was incubated over-night at 16 °C.
4.5.2 The Polymerase Chain Reaction
The polymerase chain reaction (PCR) is an in vitro assay to enzymatically amplify a specific 
segment of double stranded DNA. The assay requires two oligonucleotides (primers), which 
are complementary to flanking sequences of the target DNA segment and provide a free 3' 
hydroxyl group (3'-OH). After denaturation of the template DNA double strand the primers 
hybridize to opposite strands of DNA with their 3' ends facing each other. Then a 
thermostable DNA polymerase catalyzes the synthesis of a new strand in 5' → 3' direction 
starting at the 3'-OH group of each primer. After the first cycle these two new strands are of 
indeterminate length and serve as templates for following cycles, which result in the 
exponential accumulation of a discrete DNA product exactly the length of sequence between 
both primer ends (Saiki et al., 1988).
PCR amplifications were performed using 1-2 Units of Phusion® High-Fidelity DNA 
Polymerase (Finnzymes) according to manufacturer's instructions. PCR products were 
analyzed by agarose gel electrophoresis for yield and specificity.
4.5.3 Agarose gel electrophoresis
TBE 89 mM Tris base
89 mM Boric acid
2 mM EDTA
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10x Agarose loading buffer 50 mM Tris Cl, pH 8
50 mM EDTA
50 % (v/v) Glycerine
0.25 % (w/v) Bromphenol blue
0.25 % (w/v) Xylene cyanol
Agarose gel solution 0.8-2 % (w/v) Agarose Low EEO
or 3.5-4 % (w/v) Biozym Sieve GP Agarose
0.01 % (v/v) Ethidium bromide
TBE
The following protocol was used to separate and identify DNA fragments by their length in an 
electric field as they run through an agarose gel towards the anode. Ethidium bromide was 
used to visualize DNA fragments upon illumination with UV light and fragment size was 
estimated on basis of a molecular weight marker.
For preparation of the agarose gel the melted gel solution was poured into a gel casting 
platform and a gel comb was inserted. After the gel hardened the comb was removed and the 
gel placed in an electrophoresis tank. The tank was filled with TBE buffer until gel and 
sample slots were covered. DNA samples in 10x loading buffer and a molecular weight 
marker (GeneRuler™ DNA ladder from Fermentas) were loaded into sample wells and 
electrophoretically separated at 10 V/ cm gel distance. Ethidium bromide stained DNA 
fragments were visualized and photographed in a gel imaging system from BioRad 
(ChemiDoc™).
4.5.4 Gel extraction of DNA
Purification and concentration of DNA from agarose gels after electrophoresis was performed 
using the Zymoclean Gel DNA Recovery Kit™ (Zymo Research) according to manufacturer's 
instructions.
4.5.5 Gateway cloning
The Gateway Technology (Invitrogen) is a universal cloning method based on the site-specific 
recombination properties of bacteriophage lambda (Landy, 1989). It provides a way to move 
DNA sequences into multiple vector systems (Hartley et al., 2000).
According to this cloning strategy the desired DNA sequence is amplified by PCR using 
primers possessing the recombination sites (att-sites). Afterwards the PCR product flanked by 
att-sites is recombined into a so-called entry vector. This entry vector then can be used to 
recombine the DNA sequence of interest into different destination vectors depending on the 
intended use.
Gateway cloning was performed according to the manufacturer's instructions with slight 
modifications. PCR amplification was performed using 1-2 Units of Phusion High-Fidelity 
DNA Polymerase (Finnzymes) according to manufacturer's instructions. The recombination 
reactions were carried out over-night with half the amount of reagents as recommended.
4.5.6 Site-directed mutagenesis
Site directed mutagenesis was performed according to Stratagene's QuikChange® II Site-
Directed Mutagenesis protocol. It is a three step procedure, in which both strands of a 
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methylated double-stranded DNA vector with an insert of interest are replicated using primers 
containing the desired mutation. After replication the product is treated with Dpn I, an 
endonuclease specific for methylated and hemimethylated DNA. Dpn I digests the parental 
DNA template and thus selects the mutation-containing synthesized DNA, which is then 
transformed into competent Escherichia coli (E. coli) cells for amplification (Stratagene).
Primers for site-directed mutagenesis were designed using the online available QuikChange 
Primer Design tool (Stratagene). The mutagenesis was carried out following the 
manufacturer's instructions. All obtained plasmids were checked for correct amplification by 
sequencing of the whole insert DNA (MWG or SeqLab).
4.5.7 Generation of pSuper-based siRNA constructs
RNA interference to suppress specific gene expression was induced by using the pSUPER 
RNAi system in, which a mammalian expression vector directs intracellular synthesis of short 
interfering RNAs (siRNAs) from a polymerase-III H1-RNA gene promoter (Brummelkamp et 
al., 2002).
siRNA oligonucleotides targeting the desired sequence were designed using the online 
available program siDirect (Naito et al., 2004). Chosen sequences were verified to be specific 
for both strands by using the BLAST algorithm. An oligonucleotide was designed according 
to the following scheme: 5’-GAT CCC C-target sequence-TTC AAG AGA-complementary 
sequence-TTT TTG GAA A-3’. Another oligonucleotide was designed according to the 
following scheme: 5’-AGC TTT TCC AAA AA-target sequence-TCT CTT GAA-
complementary sequence-GGG-3’. The hybridized oligonucleotides were cloned into pSuper 
(Brummelkamp et al., 2002) digested with BglII and HindIII.
4.6 Work with prokaryotic cells
4.6.1 Bacteria strains
Name of the bacterial strain Genotype
E.coli XL10-Gold (Stratagene) Tetr D (mcrA)183 D(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F' 
proAB lacIq ZDM15 Tn10 (Tetr) Amy Camr]
E.coli DH5α (Invitrogen) F- φ80dlacZΔM15 Δ(lacZYA-argF) U169 deoR, re-
cA1 endA1 hsdR17(rk- mk+) phoA supE44 λ- thi-1 
gyrA96 relA1
E.coli BL21 (DE3) pLysS (Strata-
gene)
B F– dcm ompT hsdS(rB– mB–) gal λ(DE3) [pLysS 
Camr]
4.6.2 Materials for work with prokaryotic cells
LB medium 1 % (w/v) Tryptone
0.5 % (w/v) Yeast extract
1 % (w/v) NaCl
pH 7
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Low salt LB medium 1 % (w/v) Tryptone
0.5 % (w/v) Yeast extract
0.5 % (w/v) NaCl
pH 7.5
Agar plates (Ampicillin/Kanamycin) LB medium
1.5 % (w/v) Agar Bacteriology grade
100 g/ml Ampicillin
30 g/ml Kanamycin
Agar plates (Zeocin) Low salt LB medium
1.5 % (w/v) Agar Bacteriology grade
50 g/ml Zeocin
4.6.3 Bacterial transformation
Introduction of plasmid DNA into bacterial cells (transformation) was essentially performed 
according to the basic protocol 1 from chapter 1.8 of “Current Protocols in Molecular 
Biology” (Seidman and Struhl, 2001).
100 µl chemically competent bacteria were rapidly thawed by warming between hands and 
mixed with plasmid DNA, in general 100-500 ng. After up to 30 minutes incubation on ice 
cells were heat-shocked by placing the tube into a 42 °C water bath for 45 seconds. After heat 
shock the tube was immediately placed back on ice. 1 ml of LB medium (heated up to 37 °C) 
was added after 2 minutes incubation on ice and bacteria incubated for 1 hour at 37 °C and 
250 rpm. Afterwards bacteria were pelleted by centrifugation, resuspended in 100 µl of LB 
medium and seeded on LB agar plates containing the appropriate antibiotic. Plates were 
incubated over-night at 37 °C until bacterial colonies got visible.
4.6.4 DNA preparation
TE buffer 10 mM Tris Cl, pH 7.5
1 mM EDTA
Plasmid DNA was extracted from transformed bacteria using the Qiagen Plasmid Maxi Kit 
(Qiagen) for large-scale preparation and the GeneJETTM Plasmid Miniprep Kit (Fermentas) 
for small-scale preparation according to manufacturer's instructions. Both protocols are based 
on a modified alkaline lysis procedure, in which the differential denaturation capacities of 
chromosomal and plasmid DNA are used to separate them (Ehrt and Schnappinger, 2003). 
Isolated plasmid DNA is either concentrated and desalted by isopropanol precipitation 
(Qiagen) or by binding on a silica membrane and after several washing steps, subsequent 
elution in a smaller volume of TE buffer or sterile water (Fermentas).
4.6.5 Purification of GST fusion proteins
TNE buffer 20 mM Tris Cl pH 8.0
150 mM NaCl
1 mM EDTA
5 mM DTT
1 mM Pefabloc SC
14 µg /ml Aprotinin
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GST washing buffer 100 mM Tris Cl pH 8.0
120 mM NaCl
GST elution buffer 100 mM Tris Cl pH 8.0
120 mM NaCl
20 mM Glutathione
Purification of GST fusion proteins was essentially performed according to the basic protocol 
1 from chapter 6.6 of “Current Protocols in Protein Science” (Harper and Speicher, 2008).
BL21 bacteria were transformed with the corresponding GW-pGST plasmid. Two to three 
colonies of transformed bacteria were used to inoculate a starter culture of usually 50 ml LB 
medium supplemented with 1 % Glucose, 1 mM ZnCl2 (Merck) and the appropriate antibiotic, 
which was grown over-night at 37 °C. 
The main culture was started by dilution of the starter culture at least 1:30 in the same type of 
medium and grown at 37 °C. When the culture reached an OD600 of 0.5-0.7 gene expression of 
GST-fusion protein was induced by addition of 1 mM IPTG. Gene expression was allowed 
over-night at room temperature.
Bacteria were pelleted by centrifugation at 3500x g, resuspended in ice-cold TNE buffer and 
lysed for 30 minutes on ice in the presence of 100 µg/ ml lysozyme (AppliChem). Cells were 
solubilized by sonication and lysates cleared from cell debris by centrifugation at 10,000 g for 
30 minutes. 
The supernatant was incubated with 500 µl equilibrated Glutathione Sepharose 4B beads 
(Amersham Biosciences) per 30 ml of lysate for 1 hour at 4 °C. Beads were washed three 
times with PBS and transferred to a 0.8 x 4 cm chromatography column (Bio-Rad). After 
washing with 1 ml of GST wash buffer bound proteins were eluted in three fractions à 300 µl 
with GST elution buffer. 
Aliquots of the eluted proteins were subjected to SDS-PAGE and subsequent Coomassie 
staining in order to estimate the concentration of the purified proteins in comparison to a BSA 
standard series.
4.7 Work with eukaryotic cells (Cell culture)
4.7.1 Eukaryotic cell lines
Name of the eukaryote cell line Description
HEK 293 (ATCC CRL-1573) This is an adherent epithelial cell line derived from 
human embryonic kidney (HEK) cells transformed 
with Adenovirus 5 DNA. The Ad5 insert is integ-
rated into chromosome 19q13.2. It is a hypotriploid 
cell line with a modal chromosome number of 64, 
occurring in 30 % of cells.
HCT 116 (ATCC CCL247) This is an adherent epithelial cell line derived from 
human a colorectal carcinoma. The stem line 
chromosome number is near diploid with the modal 
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Name of the eukaryote cell line Description
number at 45 (62 %) and polyploids occurring at 
6.8 %. The cells have been reported to be positive 
for keratin by immunoperoxidase staining and for 
transforming growth factors beta 1 and 2 
(TGFβ1, 2) gene expression. This line has a 
mutation in codon 13 of the ras protooncogene
HeLa (ATCC CCL-2) This is an adherent epithelial cell line derived from 
a cervical adenocarcinoma of a 31 year old black fe-
male. 100 % aneuploidy is observed with a modal 
chromosome number of 82. HeLa cells have been 
reported to contain HPV-18 sequences, p53 gene ex-
pression was reported to be low, and normal levels 
of pRB were found.
Flp-In T-REx-HeLa 
(Invitrogen #R714-07)
This cell line was derived from HeLa. It expresses 
the Tet-repressor gene from pcDNA6/TR and con-
tains a single integrated Flp recombination target 
(FRT) site from pFRT/lacZeo resulting in expres-
sion of a lacZ-Zeocin fusion gene. This cell line can 
be used to generate a tetracycline-inducible expres-
s i o n c e l l l i n e b y c o t r a n s f e c t i n g t h e 
pcDNA5/FRT/TO expression vector containing 
your gene of interest and the Flp recombinase ex-
pression plasmid, pOG44.
Flp-In T-REx-HeLa-SIRT2, -S331A, 
-S335A, -S331/335A, -S331E, 
-S335E, -S331/335E, -ΔG320, 
-H150Y
This stably transfected cell lines were generated by 
transfection of Flp-In T-REx-HeLa cells with pO-
G44 and pcDNA5/FRT/TO or the corresponding 
GW-pcNA5/FRT/TO construct. Stable cell lines 
were obtained by selection with Hygromycin B and 
Blasticidin S.
4.7.2 Materials for cell culture work
PBS 140 mM NaCl
2.6 mM KCl
2 mM Na2HPO4
1.45 mM KH2PO4
McCoy's 5A (Gibco)
DMEM (Gibco) with 4.5 g/ l Glucose
10 mg/ml Blasticidin S (Invitrogen)
1 mg/ml Doxycyclin (Sigma)
100 mg/ml Hygromycin B (InvivoGen)
10 000 Units/ml Penicillin/10 000 µg/ml Streptomycin (Seromed)
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0.5/0.2 % (w/v) Trypsin/EDTA in PBS (Seromed)
FCS (Gibco)
Dimethyl Sulfoxide (DMSO) Cell culture grade (AppliChem)
∅ 6 cm/10 cm Tissue culture dishes (Sarstedt)
6-Well Tissue culture plates (TPP)
1 ml Cryotubes (Nalgene)
4.7.3 Cell Culture conditions
All cell lines were cultured under humidified atmosphere of 5 % CO2 at 37 °C.
HEK 293 and HeLa cells were cultured in DMEM supplemented with 10 % (v/v) FCS and 
1 % (v/v) Penicillin/Streptomycin.
HCT 116 cells were cultured in McCoy's 5A supplemented with 10 % (v/v) FCS and 1 % 
(v/v) Penicillin/Streptomycin. 
Stably transfected Flp-In T-REx-HeLa cell lines were maintained in regular DMEM 
supplemented with 15 µg/ml Blasticidin S and 200 µg/ml Hygromycin B.
4.7.4 Trypsinizing and subculturing cells from a monolayer
For subculturing of an adherent monolayer cell culture grown to confluency in a ∅ 10 cm 
tissue culture dish the old tissue culture medium was removed and cells rinsed with PBS to 
remove any residual FCS that may inhibit trypsin reaction. 1 ml Trypsin/EDTA was added to 
the cells and the dish swayed until the whole surface was covered before it was placed into a 
cell culture incubator. When cells detached from the dish surface fresh medium was added 
and an aliquot of trypsinized cells transferred to a new prepared tissue culture dish.
4.7.5 Cryo-conservation and thawing of cells
For cryo-conservation, 5-8x106 pelleted cells grown to log phase were resuspended in 1 ml 
FCS supplemented with 10 % (v/v) DMSO and transferred into a cryotube. After incubation 
on ice for 30 minutes, the cryotubes were wrapped in several layers of tissue paper, put into 
an isolating box and slowly cooled down for 16-48 hours at -80 °C. Afterwards, the cryotubes 
were transferred to -150 °C for long-term storage.
For thawing of frozen cells, cryotubes were rapidly thawed in a water bath at 37 °C. 
Immediately after melting of ice crystals, cells were suspended in 10 ml culture medium, 
pelleted by centrifugation, resuspended in 10 ml culture medium and transferred to an 
appropriate culture dish or flask.
4.7.6 Transfection of DNA into eukaryotic cells
Calcium Phosphate Transfection
2x Hebs buffer 274 mM NaCl
42 mM HEPES
9.6 mM KCl
1.5 mM Na2HPO4
pH 7.1
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HEPES buffer 142 mM NaCl
10 mM HEPES
6.7 mM KCl
pH 7.3
The transient transfection of HEK293 and HeLa cells was performed according to the calcium 
phosphate method (Chen and Okayama, 1988). This method is based on the precipitate 
formation of calcium-phosphate-DNA complexes, which are taken up by cells through 
endocytosis.
The day prior to the transfection, about 1x106/4x105 cells were seeded on ∅ 10 cm/∅ 6 cm 
tissue culture dishes. For transfection, 20 µg/4 µg of total DNA was diluted in 500 µl/200 µl 
250 mM CaCl2. Subsequently, 500 µl/200 µl 2x Hebs buffer was added, the solution briefly 
vortexed for 3 seconds and incubated for 15 minutes at ambient temperature. Afterwards the 
solution was pipetted onto the cell monolayer. The dishes were swayed and put back into the 
incubator. After 5-6 hours incubation time, the cells were freed from residual precipitate by 
washing with 5 ml/2 ml HEPES buffer. Subsequently, fresh medium was added.
Calcium phosphate transfection of HeLa cells was performed according to the standard 
instructions with slight modifications. For transfection of a 40 % confluent ∅ 10 cm plate of 
HeLa cells 20 µg DNA was diluted in 950 µl 1x Hebs buffer, pH 6.95. Precipitate formation 
was induced by adding 50 µl 2.5 M CaCl2.
Cationic Lipid-mediated Transfection
Cationic lipid-mediated transfection of eukaryotic cells is based on the ability of positively 
charged (cationic) lipids to form complexes with nucleic acid polymers due to ionic 
interactions. The cationic and lipophilic character of these aggregates then allows crossing of 
the negatively charged and hydrophobic cell membrane of target cells (Felgner et al., 1987).
Transfection of HeLa cells was performed by using ExGen 500 (Fermentas) according to 
manufacturer's instructions with an ExGen 500/DNA ratio of 3.3:1.
FuGeneHD (Roche) was used for the transfection of HCT 116 cells according to the 
manufacturer’s instructions with an FuGeneHD/DNA ratio of 6:2.
4.7.7 Preparation of cell lysates
RIPA buffer 10 mM Tris Cl, pH 7.4
150 mM NaCl
1 % Nonidet P40 Substitute
1 % Sodium deoxycholate
0.1 % SDS
CoIP buffer 10 mM HEPES, pH 7.5
50 mM NaCl
30 mM tetra-Sodium pyrophosphate
50 mM Sodium fluoride
5 µM Zinc chloride
0.2 % Triton X-100
10 % Glycerine
pH 7.05
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Phosphatase Inhibitors 100 µM Sodium ortho-vanadate
20 mM Sodium ß-glycerophosphate
0.05 µM Ocadaic acid
50 mM Sodium fluoride
Cells of a ∅ 10 cm tissue culture dish grown to confluency were gathered in the supernatant 
or fresh culture medium and pelleted by centrifugation at 200x g for 3 minutes at 4 °C. 
Pelleted cells were washed in 5 ml PBS and pelleted by centrifugation again.
Cell pellets were stored at -20 °C for at least 1 hour before lysis in 750 µl CoIP buffer or 
RIPA buffer supplemented with ProteoBlock Protease Inhibitor Cocktail (Fermentas) and 
phosphatase inhibitors. CoIP-lysates were incubated on ice for 30 minutes before cell debris 
was spun down at 16 000x g for 30 minutes at 4 °C. RIPA-lysates were sonicated for 
15 minutes at high level in the Bioruptor from Diagenode at 4 °C before cell debris was spun 
down. The supernatant was transferred to a new reaction tube and used immediately for 
further analysis.
4.8 Work with proteins
4.8.1 Immunoprecipitation
This method describes the isolation of an antigen by binding to a specific antibody, which is 
attached to a sedimentable matrix. For this work proteins were immunoprecipitated from 
whole cell lysates using protein A or protein G-conjugated sepharose. Protein A and protein G 
from Staphylococcus aureus are immunoadsorbants that can non-covalently bind antibodies 
(Bonifacino et al., 2001).
For immunoprecipitation the suitable antibody (5 µl of a polyclonal antiserum, 1 µg of 
purified monoclonal antibody or 10 µl of culture supernatant containing monoclonal 
antibody) was added to 700 µl of whole cell lysate and incubated for 2 hours or over-night at 
4 °C while mixing end over end in a tube rotator. Meanwhile 25 µl of 50 % protein A- or G 
sepharose bead slurry were washed twice with 0.5 ml lysis buffer. Then the lysate-antibody 
mixture was combined with the prepared sepharose beads and incubated 1 to 2 hours at 4 °C 
while mixing end over end in a tube rotator.
After incubation the protein-antibody-complexes bound to the sepharose beads were 
sedimented at 200x g for 1 minute in a microcentrifuge and the supernatant aspirated using a 
disposable pipet tip connected to a vacuum aspirator. To remove unspecific bound proteins 
beads were resuspended in 1 ml ice-cold lysis buffer and sedimented. After aspiration of the 
supernatant this washing step was repeated 2 to 3 times. Immunoprecipitated proteins were 
used for enzymatic assays (4.9 ) or directly analyzed by SDS-PAGE (4.8.2 ) and immunoblot 
(4.8.5 ).
4.8.2 Denaturing (SDS) Discontinuous Polyacrylamide Gel 
Electrophoresis (SDS-PAGE)
2x/4x Sample buffer 160 mM/320 mM Tris Cl, pH 6.8
20 %/40 % (v/v) Glycerine
10 %/8 % (w/v) SDS
0.25 %/0.5 % (w/v) Bromphenol blue
100 mM/200 mM ß-Mercaptoethanol
4. Experimental Procedures 70
Laemmli buffer 25 mM Tris base
250 mM Glycerine
0.1 % (w/v) SDS
Discontinuous polyacrylamide gel electrophoresis under denaturing conditions (presence of 
0.1 % SDS) separates proteins based on molecular size as they move through a gel matrix 
toward the anode. The polyacrylamide gel is cast as a separating gel topped by a stacking gel 
and secured in an electrophoresis apparatus.(BioRad). Sample proteins are solubilized by 
boiling in the presence of SDS (sample buffer), applied to a gel lane and separated 
electrophoretically. Binding of SDS to the denatured proteins generates a negative net charge 
of the proteins due to its anionic properties and allows separation solely by molecular weight 
(Gallagher, 2001). 
The SDS-PAGE was performed according to the Laemmli buffer system (Laemmli, 1970) 
with a 5 % stacking gel and 10-15 % separating gels. The molecular weight of separated 
proteins was estimated by comparison with the PageRuler™ Prestained Protein Ladder 
(Fermentas).
4.8.3 Rapid Coomassie blue staining
Fixing solution 25 % (v/v) Isopropanol
10 % (v/v) Acetic acid
Rapid Coomassie blue staining solution 10 % (v/v) Acetic acid
0.006 % (w/v) Coomassie brilliant blue G-250
Detection of protein bands in a polyacrylamide gel by Coomassie blue staining depends on 
nonspecific binding of a dye, Coomassie brilliant blue R, to proteins. In this procedure 
proteins separated by SDS-PAGE were precipitated by gently shaking the polyacrylamide gel 
in the fixing solution for 30 minutes. Then the location of the precipitated proteins were 
detected by exchanging the fixing solution for the rapid Coomassie blue solution and 
incubation for 1 hour. Background staining was removed by incubation with water containing 
a tissue paper over-night. All incubations took place at room temperature. The gel was 
photographed and dried on Whatman paper to maintain a permanent record (Echan and 
Speicher, 2002).
4.8.4 Electroblotting from polyacrylamide gels
The electrophoretic transfer of proteins from polyacrylamide gels on retentive membranes 
(nitrocellulose or PVDF) results in a replica of the original gel pattern, which can be 
visualized by Ponceau S staining and detected by respective antibodies (= immunoblot or 
Western blot). The method was essentially performed according to Towbin (Towbin et al., 
1979).
Semi-dry transfer buffer 25 mM Tris base
192 mM Glycine 
20% (v/v) methanol
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Tank blot transfer buffer 25 mM Tris base
192 mM Glycine 
0.1% (w/v) SDS
For the transfer the polyacrylamide gel and the membrane were soaked in the respective 
transfer buffer and packed between three layers of Whatman papers, which were soaked in the 
buffer as well. PVDF membranes were pre-soaked in methanol. For even blotting results it 
was necessary to remove all air bubbles between the different sheets of the so called 
“sandwich”. Then the sandwich was placed in a semi-dry blotting chamber between two 
electrode plates or into a tank-blot apparatus. Proteins were transferred to the membrane for 
1 hour at 2 mA/ cm2 of membrane size.
Ponceau S staining
Ponceau staining solution 0.2 % (w/v) Ponceau S
3 % (v/v) Trichloroacetic acid
Transfer efficiency was controlled by incubating the membrane in Ponceau staining solution 
for 2 minutes. Excessive staining was removed by washing off the membrane with water.
4.8.5 Immunoblot detection
Detection of a specific protein transferred by Western blotting on a membrane was achieved 
by a two-step antibody incubation, in which first a primary antibody specifically bound the 
protein of interest. Then a secondary antibody was used that targeted the invariable part of the 
primary antibody and was conjugated with horseradish peroxidase (HRP). Protein-antibody 
complexes were visualized by a chemiluminescence reaction, in which a substrate was locally 
turned-over under emission of light by the peroxidase. The emission was detected by a CCD 
camera imaging device.
TBS-T 20 mM Tris base
137 mM NaCl
0.05 % (v/v) Tween-20
Blocking buffer 5 % (w/v) Nonfat dried milk powder
TBS-T
Antibody buffer 5 % (w/v) BSA
TBS-T
For immunodetection of proteins the membrane was incubated with blocking buffer for 
30 minutes at room temperature to block unspecific binding sites. After three washing steps 
with TBS-T the membrane was incubated with the primary antibody, diluted in antibody 
buffer for 1 hour at room temperature or over-night at 4 °C. Afterwards the membrane was 
thoroughly washed thrice and incubated with the secondary antibody, diluted in blocking 
buffer for 30 minutes at room temperature. Prior to detection the membrane was washed for 
30 minutes and at least three times with TBS-T. The ECL solution from Pierce was used as a 
substrate according to manufacturer's instructions. The detection was carried out with a 
computer-assisted camera (LAS-3000, Fuji).
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4.8.6 Autoradiography
Autoradiography was used to detect radioisotope-labeled proteins or peptides in dried gel with 
commercially available autoradiography films. These films are covered with an emulsion of 
silver halide grains, which interact with emitted ionizing radiation. The resulting latent image 
is then amplified by incubation with a developer (Bundy, 2001).
For detection of 32P-labeled samples an intensifying screen was located on the other side of a 
autoradiography film, which converted the ionizing radiation to blue or green light thereby 
intensifying the signal.
Detection of 35S-labeled samples was enhanced by fluorography. For that purpose the 
Coomassie-stained gel was soaked in scintillant prior to drying. The reagent emitted visible 
light upon absorbing ionizing radiation.
For both detection methods the dried gel and the autoradiography film (SuperRX FUJI ) were 
incubated in a light-tight cassette at -80 °C. After exposure the cassette was warmed to room 
temperature and manually processed in a developer and fixing solution from Tetenal 
according to manufacturer's instructions.
4.9 Enzymatic Assays
4.9.1 Acetylation Assay
In this gel assay, a lysine acetyltransferase catalyzed acetylation of substrates with acetyl-CoA 
as the coenzyme. Acetylated proteins were separated from each other, as well as from free 
acetyl-CoA, by SDS-PAGE (4.8.2 ) for subsequent detection by immunoblot (4.8.5 ). The in  
vitro assay was essentially performed according to the basic protocol 2 from chapter 14.11 of 
“Current Protocols in Protein Science” with slight differences (John E. Coligan, 2011.).
5x Buffer A1 250 mM Tris Cl, pH 8.0
50 % (v/v) Glycerine
5 mM DTT
0.5 mM EDTA
5x Buffer A2 250 mM Tris Cl, pH 8.0
50 % (v/v) Glycerine
0.5 M NaCl
20 mM MgCl2 
1 mM ZnCl2
HDAC inhibitors 10 mM Sodium butyrate
3 µM TSA
5 mM Nicotinamide
10 µM AGK2
A 20 µl acetylation reaction was prepared in a 1.5 ml sterile microcentrifuge tube on ice 
containing 4 µl of 5x buffer A, HDAC inhibitors, ProteoBlock Protease Inhibitor Cocktail 
(Fermentas), 0.5 µg substrate and 0.25 mM acetyl-CoA. If there were many samples, a master 
mix was prepared.
The lysine acetyltransferase was diluted to a concentration of 250 ng/µl in 1x buffer A and 
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1 µl enzyme added to a reaction mix. The tube was gently mixed and transferred into a 
Thermo Shaker (BioRad) preheated to 30 °C. After an incubation at 30 °C at 1400 rpm for 
30 minutes the reaction was terminated by addition of 7 µl 4x sample buffer (4.8.2 ). The 
samples were analyzed by SDS-PAGE (4.8.2 ) and immunoblot (4.8.5 ).
4.9.2 Deacetylation Assay
The following protocol describes an enzymatic assay to detect SIRT2 activity by using 
purified porcine tubulin (Cytoskeleton, T240) as a substrate.The deacetylation of tubulin was 
detected through immunoblot (4.8.5 ) with a specific antibody detecting acetylated tubulin.
A 19 µl deacetylation reaction was prepared in a 1.5 ml sterile microcentrifuge tube on ice 
containing 4.8 µl of 5x buffer A1 (4.9.1 ), ProteoBlock Protease Inhibitor Cocktail 
(Fermentas), 0.5 µg tubulin and 1 µg GST-SIRT2. If there were many samples, a master mix 
was prepared.
The enzymatic reaction was initiated by adding 2.5 mM NAD+ cofactor (5 µl). The reaction 
tube was gently mixed and transferred into a Thermo Shaker preheated to 30 °C. After an 
incubation at 30 °C and 1400 rpm for up to 90 minutes the reaction was terminated by 
addition of 8 µl 4x sample buffer (4.8.2 ). The samples were analyzed by SDS-PAGE (4.8.2 ) 
and immunoblot (4.8.5 ).
4.9.3 Kinase Assay
The following protocol describes an enzymatic assay to detect the phosphorylation of a 
substrate by CDK5. The assay was essentially performed according to a protocol from Sigma-
Aldrich to measure CDK5 activity with slight differences. Purified GST-fusion proteins (4.6.5
) were used as substrates and CDK5 was transiently overexpressed in HEK293 cells (4.7.6 ) 
and immunoprecipitated (4.8.1 ). Results were evaluated by SDS-PAGE (4.8.2 ) and 
autoradiography (4.8.6 ).
Kinase assay buffer 25 mM MOPS, pH 7.2
12.5 mM Sodium ß-glycerophosphate
25 mM MgCl2
5 mM EGTA
2 mM EDTA
0.25 mM DTT
(0.25 mM ATP)
Kinase dilution buffer 20 % (v/v) kinase assay buffer without ATP
Immunoprecipitated p35/CDK5 complexes were washed once with kinase dilution buffer for 
equilibration and gathered in 10 µl of the same buffer. 1 µg GST-substrate was diluted in 
sterile water and added to the kinase solution. 2 µC [γ-32P]-ATP were added to 60 µl kinase 
assay buffer. Out of this “hot mix” 5 µl were used to initiate the enzymatic reaction. The 
reaction tube was gently mixed and transferred into a Thermo Shaker (BioRad) preheated to 
30 °C. After an incubation at 30 °C and 1400 rpm for 15 minutes the reaction was terminated 
by addition of 8.3 µl 4x sample buffer (4.8.2 ). The samples were separated by SDS-PAGE 
(4.8.2 ) and the gel subjected to a Coomassie blue staining (4.8.3 ). Afterwards the gel was 
dried on Whatman paper and analyzed by autoradiography (4.8.6 ).
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4.9.4 Phosphatase Assay
The following protocol describes an enzymatic assay to dephosphorylate proteins with a 
commercially available unspecific phosphatase (FastAP™, Fermentas). The assay was 
essentially performed according to manufacture's instructions. Results were evaluated by 
SDS-PAGE (4.8.2 ) and immunoblot (4.8.5 ).
1x Alkaline phosphatase buffer 10 mM Tris Cl, pH 8
5 mM MgCl2
100 mM KCl
Phosphatase inhibitors 100 µM Sodium ortho-vanadate
20 mM Sodium ß-glycerophosphate
0.05 µM Ocadaic acid
50 mM Sodium fluoride
Immunoprecipitated substrates (4.8.1 ) were washed once with 1x alkaline phosphatase buffer 
for equilibration and gathered in 5 µl of 10x FastAP buffer (Fermentas). 37 µl sterile water 
were added to achieve a reaction volume of 50 µl. As a negative control phosphatase 
inhibitors were included in the reaction. The assay was initiated by addition of 8 µl enzyme 
and incubated at 37 °C and 1400 rpm in a Thermo Shaker (BioRad). After 1 hour the reaction 
was terminated by addition of 16.7 µl 4x sample buffer (4.8.2 ) and the samples were 
analyzed by SDS-PAGE (4.8.2 ) and immunoblot (4.8.5 ).
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6. Appendices
6.1 Abbreviations
A Ampere
A.dest. Destilled water
aa Amino acid
Ab Antibody
AD Alzheimer's disease
ADP Adenosine diphosphate
Amp Ampicillin
AMP Adenosine monophosphate
APS Ammonium persulfate
ATCC American Tissue Culture Collection
ATP Adenosine triphosphate
bp Base pair
BSA Bovine serum albumine
°C Degree Celsius
C- Carboxy-
ca. Circa
CDK Cyclin-dependent kinase
CFP Cyan-fluorescent protein
CMV Cytomegalie virus
Da Dalton
DMEM Dulbecco's modified Eagle's medium
DMSO Dimethyl sulfoxid
DNA Desoxyribonucleic acid
DSB Double strand break
DTT Dithiothreitol
DUB Deubiquitinating enzyme
DUSP Dual-specific enzyme
E Glutamate
E. coli Escherichia coli
e.g. For example
ECL Enhanced chemoluminescense
EDTA Ethylene-diamine-tetra-acedic acid
EGTA Ethylene-glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
EST Expressed sequence tag
et al. at alii
FAD Flavin adenine dinucleotide
FAK Focal adhesion kinase
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FAO Fatty acid oxidation
FCS Fetal calf serum
g Gram
g Gravitation constant
GFP Green fluorescent protein
HAT Histone acetyltransferase
HDAC Histone deacetylase
HeBS Hepes buffered saline
HEK Human embryonic kidney
HIF-1α Hypoxia inducible factor 1α
HRP Horseradish peroxidase
IgG Immunoglobuline G
IMP Inner membrane peptidase
IMS Intermembrane space
IP Immunoprecipitation
IPTG Isopropyl-β-D-1-thiogalactopyranoside
k Kilo
K Lysine
KAT Lysine acetyltransferase
KDAC Lysine deacetylase
KDM Lysine specific demethylase
KMT Lysine methyltransferases
l Liter
LB Luria Broth
M Molar (mol/l)
m Milli
m Meter
MARH Mono-ADP-ribose-protein hydrolase
MART Mono-ADP-ribosylating enzyme
MBP Myelin basic protein
MCS Multiple cloning site
MEF Murine embryonic fibroblast
min Minute
MIP Mitochondrial intermediate peptidase
MPP Mitochondrial processing peptidase
mRNA Messenger RNA
MS Mass spectrometry
n Nano
N- Amino-
NAD+ Nicotinamide adenindinucleotide
NAM Nicotinamide
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NAMPT NAM phosphoribosyltransferase
NES Nuclear export signal
NLS Nuclear localization signal
O-AADP Ortho-Acetyl-ADP
OD Optical density
OL Oligodendrocyte
p.a. Pro analysi
PAGE Polyacrylamide gel electrophoresis
PAR Poly-ADP-ribose
PARG Poly-ADP-ribose glycohydrolase
PARP Poly-ADP-ribose polymerase
PBS Phosphate buffered saline
PD Parkinson's disease
PPAR Peroxisome proliferator-activated receptors
PPP Phospho-protein phosphatases
PRMT Protein arginine methyltransferases
PTM Posttranslational modification
PTP Protein tyrosine phosphatases
RNA Ribonucleic acid
ROS Reactive oxygen species
rpm Rounds per minute
S Serine
SAM S-adenosyl-L-methionine 
shRNA Short hairpin RNA
SIM SUMO-interaction motifs
SOD Superoxide dismutase 
SREBP Sterol response element binding protein
SUMO Small ubiquitin-related modifiers
TE Tris-EDTA
TIM Translocase of the inner membrane
TOM Translocase of the outer membrane
U Unit
UBD Ubiquitin-binding domain
v/v volume per volume
w/v weight per volume
WB Western blot
wt Wildtype
Y Tyrosine
YFP Yellow fluorescent protein
µ Micro
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